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Summary 
Patients with familial hypercholesterolemia (FH) have an increased risk of premature 
atherosclerosis and coronary artery disease (CAD). Recently, inflammation has been 
suggested to play a major role in the development of atherosclerosis, and indeed children 
with FH have previously been suggested to have increased levels of selective inflammation 
markers. The aim of this study was to increase the knowledge about inflammation in the 
early steps of atherosclerosis. 
Sixty-two FH children (aged 7-20 years) and twenty-two sex- and age-matched control 
children were included. Quantification of the circulating proteins soluble (s)E-selectin, 
vascular cell adhesion molecule-1 (sVCAM-1), intercellular adhesion molecule-1 (sICAM-
1), adiponectin and leptin was performed in serum samples from each subject. Furthermore, 
gene expression levels of tumor necrosis factor α (TNFα), ICAM-1 and leptin receptor in 
peripheral blood mononuclear cells (PBMCs) were determined by quantitative reverse 
transcription polymerase chain reaction (Q-RT-PCR).  
The main results showed: i) FH children have increased TNFα gene expression levels and a 
tendency to increased sE-selectin levels compared to control children; ii) FH boys have 
enhanced sE-selectin and sVCAM-1 levels compared to FH girls; iii) FH boys above 15 
years have increased levels of sE-selectin compared to age-matched FH girls; iv) FH boys 
below 15 years have enhanced levels of sVCAM-1 compared to FH girls in the same age 
group; v) FH girls have enhanced leptin levels compared to FH boys; vi) there was a 
tendency to enhanced leptin levels, whereas adiponectin levels were decreased in FH 
children above 15 years compared to FH children below 15 years.  
In conclusion, our results may support the notion of increased inflammation in FH children. 
Furthermore, the results may also indicate that the gender difference in the levels of early 
atherosclerotic markers may be established already in childhood and may thus partly explain 
the gender difference in the risk of CVD. 
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1. Introduction 
1.1 Familial Hypercholesterolemia 
Late in the 19th century, the Norwegian pathologist Francis Harbitz described the first 
cases of xanthomatosis (1). The pioneering discovery was followed by several 
observations of xanthomatosis associated with hypercholesterolemia and 
cardiovascular disease (CVD) led by the physician Carl Müller. He subsequently 
claimed that hypercholesterolemia was a strong predictor in the development of CVD 
(1). Although the mechanism behind the disease was unknown, Müller regarded the 
disease to be an inherited metabolic disorder, and called it the Müller-Harbitz disease. 
These observations and statements were the first steps in the discovery of the 
autosomal dominant disease known today as Familial Hypercholesterolemia (FH). 
The disease is characterised by an elevated level of both total cholesterol and low 
density lipoprotein cholesterol (LDL-C) which give rise to xanthomatosis, deposits of 
cholesterol in peripheral tissues and accelerated atherosclerosis thereby increasing the 
risk of premature coronary artery disease (CAD) (2).  
In 1985 Brown and Goldstein were awarded the Nobel price for their discovery of the 
low density lipoprotein receptor (LDL-R) in which gene mutations are the pathogenic 
cause for FH (3). Its function is crucial in regulating the cholesterol homeostasis and 
thus mutations in the gene will result in enhanced cholesterol levels seen in FH 
patients. 
 14 
1.1.1 Genetics and Prevalence 
The high affinity LDL-R binds apolipoprotein (apo) E- and apoB-containing 
lipoprotein particles, including very low density lipoprotein (VLDL), intermediate 
density lipoprotein (IDL), LDL and a subclass of high density lipoprotein (HDL), and 
is mainly expressed on liver cells (3). Hence, the LDL particle is taken up by the cells 
through a receptor-mediated endocytosis (Figure 1). This pathway enables the LDL-C 
to be released in the cell and the LDL-R to recycle multiple times. The gene encoding 
the LDL-R is located on chromosome 19 and consists of 18 exons separated by 17 
introns. 
FH is caused by mutations in the LDL-R gene (3). Worldwide, more than 800 
different mutations in the LDL-R gene have been found (4). The majority of these 
results in one of five phenotypes of receptors: 1) none-detectable, 2) transport 
defective, 3) ligand defective, 4) internalization defective and 5) recycling defective 
(2). Approximately 1 of 500 people is estimated to be affected by heterozygous FH, 
which is calculated to approximately 10 million people worldwide (5). In certain 
populations like the Icelandic, the French Canadians and the Norwegians, an 
increased prevalence is estimated. The estimated prevalence is set to approximately 
1/300 in Norway (6), and FH is thus affecting approximately 16000 people which 
makes it a common inherited disease in Norway. Homozygous FH patients are rare 
(1/1000000) (2), and herein the term FH will further refer to heterozygous FH 
patients. 
In Norway, approximately 130 different mutations have been identified in the LDL-R 
gene among FH patients (6). However, three founder mutations account for 
approximately 40 % of mutations found in the FH patients in the Norwegian 
population. These are FH Elverum, FH Svartor and FH C210G, accounting for 25%, 
8% and 8%, respectively (7). Both FH Elverum and Svartor predict none-detectable 
LDL-R, while FH C210G results in a ligand defective receptor. The increased 
prevalence in Norway can hence be explained by a founder effect. This founder effect 
is reflected in a population established of a few original founders carrying the 
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mutations mentioned above (5), due to the Norwegian geography, landscape and 
climate (8).  
 
Figure 1. Fate of an LDL particle and its receptor after endocytosis. After an LDL particle binds to an 
LDL receptor on the plasma membrane, the receptor-ligand complex is internalized in a clathrin-coated 
pit that pinches off to become a coated vesicle. The clathrin coat then depolymerizes to triskelions, 
resulting in an early endosome. This endosome fuses with a sorting vesicle, known as a late 
endosome, where the low pH (≈5) causes the LDL particles to dissociate from the LDL receptors. A 
receptor-rich region buds off to form a separate vesicle that recycles the LDL receptors back to the 
plasma membrane. A vesicle containing an LDL particle may fuse with another late endosome but 
ultimately fuses with a lysosome to form a larger lysosome. There, the apolipoprotein B of the LDL 
particle is degraded to amino acids and the cholesterol esters are hydrolyzed to fatty acids and 
cholesterol. Abundant imported cholesterol inhibits synthesis by the cell of both cholesterol and LDL 
receptor protein. LDL= low density lipoprotein. (9) 
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1.1.2 Characteristics and Diagnosis of FH 
Because of the reduced amount of or non-functional LDL-R in FH patients, clearance 
of LDL-C is impaired and results in two- to three-fold elevated plasma levels of 
LDL-C (3;10). The elevated LDL-C levels may in turn result in cholesterol 
accumulations in extravascular tissues forming premature atherosclerosis as well as 
the typical characteristics of FH: Achilles tendon xanthomas and corneal arcus (11).  
Previously, FH patients were diagnosed clinically by observations of inherited 
hypercholesterolemia and xanthomatosis (12). Today, FH patients are primarily 
diagnosed by an identification of a mutation in the LDL-R gene using a 
deoxyribonucleic acid (DNA) test. The most cost-effective approach to diagnose FH 
is screening family members of an already diagnosed patient (12;13), and the DNA 
test is the most specific method doing this (12). Detection of inherited 
hypercholesterolemia is still a diagnostic criterion in families without an identified 
mutation by DNA-test. Children and young adults from these families can be 
diagnosed by a total and LDL cholesterol level above 5.5 mmol/l and 3.5 mmol/l, 
respectively (6). 
In Norway, approximately 3900 patients from approximately 1000 different families 
have a diagnosis verified by a DNA test (6).  
1.1.3 Treatment 
The risk of premature onset of atherosclerosis in patients with FH require an early 
initiation of lifelong cholesterol reducing therapy among patients with this disorder 
(14). Treatment goal for adult FH patients, according to the European Atherosclerosis 
Society1, is level of total cholesterol below 4.5 mmol/l and LDL-C below 2.5 mmol/l 
(15), which may be implemented by a treatment combined of drug and diet. Children 
                                              
1 Adult FH patients are considered as high risk subjects. 
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with FH are treated towards a target LDL-C below 3.35 mmol/l (minimal) or 2.85 
mmol/l (ideal) (16). 
Pharmacological Treatment 
Statins or Hydroxymethylglutaryl Coenzyme A (HMG CoA) reductase inhibitors is 
the most preferred drug used in adult FH patients (14). They act by inhibiting the 
enzyme, HMG CoA reductase, which catalyzes the rate limiting step of cholesterol 
biosynthesis (17). As an effect the intracellular concentration of cholesterol is 
lowered and to compensate the cell’s need for cholesterol, expression of LDL-R is 
up-regulated. The cholesterol-reducing effect of statins is about 25-45% depending 
on the dosage and drug (17;18). A new approach to reduce LDL-C is combining 
statins with ezetimibe, a selective cholesterol inhibiting drug which reduces the 
absorption of dietary and biliary cholesterol by preventing its transport through the 
intestinal wall (5). In co-administration with a statin, ezetimibe may result in an 18% 
incremental decrease in LDL-C. LDL-apheresis is mostly used in the LDL-C 
lowering therapy of homozygous FH patients, but is also used in heterozygous FH 
patients not responding to conventional drug therapy. 
Until recently, optimal treatment in children with FH have been resins and 
consumption of a diet low in saturated fat and cholesterol (19). Resins act by binding 
bile salts in the intestine, a major pool of cholesterol, preventing their reabsorption 
and promoting their excretion without being absorbed in the intestine (16). As a 
result, an increased number of LDL-R is expressed on the liver cell surface and the 
clearance of LDL-C from the circulation is increased. However, their reducing effect 
of total and LDL cholesterol is modest (13% to 20%), and the compliance is poor due 
to their gastrointestinal side effects and poor palatability. Adverse effects as increased 
triglycerides levels and interaction with the absorption of some medications and fat-
soluble vitamins may occur. 
Numerous studies have shown that short-term use of statins in FH children is safely 
and efficient (20-23). Statin treatment in FH children (aged 8 to 18 years) have been 
evaluated in a meta-analysis of six randomized, double-blind, placebo-controlled 
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trials (RCTs) (24). Together the RCTs, gave a comparison of 798 children with a 
treatment duration ranging from 12 to 104 weeks. The results showed significantly 
reduced levels of total cholesterol, LDL-C and apoB, whereas HDL-C and apoA1 
were significantly increased after statin treatment. Moreover, comparing the statin-
treated children with the placebo-treated children, no significant differences in the 
occurrence of adverse events, sexual development, muscle toxicity or liver toxicity 
were observed. These results support the notion that statin treatment of FH children is 
efficient and safe. Another finding which emphasise statin treatment in children, is 
the observation of improved endothelial function in FH children after using statins in 
a short period compared to FH children receiving placebo (22).  
American Heart Association (AHA) has announced a scientific statement on drug 
therapy of high-risk lipid abnormalities in children and adolescents (16). Current 
modifications of the National Cholesterol Education Program (NCEP) guidelines, 
concerning FH children, include: 
• For children meeting criteria for starting lipid-lowering drug therapy2, a statin 
is recommended as first line treatment 
• For children with high risk lipid abnormalities, the presence of additional risk 
factors or high-risk conditions may also lower the recommended cut-point 
LDL-C level for initiation of drug therapy, lower the desired target LDL-C 
levels, and in selected cases, may prompt considerations for initiation below 
the age of 10 years. These risk factors and high-risk conditions are listed in 
Table 1. 
                                              
2 Drug therapy are considered after 6- to 12-months trial of fat- and cholesterol-restricted dietary management by these 
conditions: 1) LDL-C remains above 4.9 mmol/l or 2) LDL-C remains above 4.1 mmol/l, and there is a positive family 
history of premature CVD and presence of 2 or more risk factors in the child or adolescent after vigorous attempt to control 
these risk factors (16). 
 19
Table 1. Additional risk factors or high-risk conditions for children with high-risk lipid 
abnormalities. 
  
 
Male gender 
 
Strong family history of premature cardiovascular disease or events 
 
Presence of associated low HDL-C, high triglycerides, small dense LDL particles 
 
Presence of overweight or obesity and aspects of the metabolic syndrome3  
 
Presence of other medical conditions associated with an increased atherosclerotic risk e.g diabetes 
 
Presence of hypertension 
 
Current smoking and passive smoking exposure 
 
Presence of novel and emerging risk factors and markers e.g. elevated lipoprotein(a), homocystein, C-
reactive protein 
 
Adapted from McCrindle et al (16).  
 
Lifestyle Recommendations 
Together with drug therapy, all FH patients are advised to follow certain lifestyle 
recommendations, in children under the age of statin treatment this is the first line of 
treatment to lower the cholesterol level (5). Lifelong diet recommendations include 
low intake of cholesterol (200 mg/day) and fat, especially saturated fat, which should 
not account for more than 30% and 10% of the total calories per day, respectively. 
However, this diet should not begin before the age of two because of growth and 
neurological development in young children. According to AHA Dietary Guidelines, 
a healthy fatty acid composition rich in unsaturated fatty acids have beneficial effects 
on HDL-C, LDL-C and triglycerides and hence should substitute saturated fat in the 
diet (25). In addition, a Mediterranean diet rich in vegetables, fruits, legumes, whole 
grains, fish and vegetable oils is reported to have beneficial effects on a dyslipidemic 
                                              
3 Children meeting three of these five criteria are defined to have metabolic syndrome: 1) Body mass index (BMI) above 
the 97th percentile; 2) Triglycerides above the 95th percentile; 3) HDL-C below the 5th percentile; 4) systolic or diastolic 
blood pressure above the 95th percentile; 5) Impaired glucose tolerance as defined by the American Diabetes Association. 
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profile and thus in the prevention of CVD (26-28). The beneficial effect of this diet is 
probably due to the synergy effect of dietary fibre, antioxidants and unsaturated fatty 
acids (29). Certain soluble fibres (oat products, pectin, psyllium and guar gum) acts 
by reducing LDL-C (25), and dietary antioxidants is hypothesized to reduce the 
oxidative stress (30) which creates oxidised LDL (oxLDL), both shown to be 
involved in the atherosclerosis process (31). Another documented cholesterol-
reducing agent is plant sterols, which is found naturally in several vegetable oils and 
fats (25;32). Plant sterols can be isolated and used as fortification of margarines (32). 
Consumption of 2 to 3 g plant sterols per day has been shown to decrease total 
cholesterol and LDL-C levels by 9% to 20% (25). Omega-3-fatty acids derived from 
fish (eicosapentaenoic acid and docosahexaenoic acid [DHA]) or vegetable products 
(α-linoleic acid) have been shown to have a cardioprotective effect (25;33). In a 
cholesterol-reducing diet, at least 2 servings of fish per week, 5 servings of fruits and 
vegetables per day and >25 g fibres a day, included soluble fibres, are recommended 
(25).  
Physical activity is highly associated with prevention of CVD because of its 
favourable effect on blood pressure, triglyceride levels, LDL-C and HDL-C (28). A 
general recommendation, concerning FH patients, is engaging in at least 30 min 
moderate-intensity physical activity per day. 
The numerous evidences for adverse effects of cigarette smoking on CVD have 
generated general recommendations against smoking (25). 
1.1.4 None Modifiable Risk Factors for CAD 
The gender difference in the risk of developing CAD is well documented (34;35). In 
pre-menopausal women the risk of developing CAD is significantly lower than in 
age-matched men, however this protection disappear after menopause, as the risk is 
similar to or even higher in women than in men (34). Several studies have been 
conducted to understand the mechanism behind this pre-menopausal protection, 
suggesting sex hormones playing a role (35;36). Oestrogens are shown to mediate 
several beneficial effects related to the pre-menopausal protection. First, endogenous 
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oestrogens are shown to enhance release of endothelial-derived nitric oxide (NO) 
which increases expression of reactive oxygen species (ROS) eliminating enzymes 
(34;35;37). In atherogenesis, ROS are pivotal, contributing to endothelial dysfunction 
and generating oxLDL, modifications involved in the development of atherosclerosis. 
Moreover, oestrogens have been shown to decrease expression of nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase an enzyme generating ROS. Other 
reported effects of oestrogens are promoting vascular smooth muscle cell (SMC) 
relaxation, inhibiting vascular SMC proliferation/migration, suppressing vascular 
inflammation and exerting direct antioxidant effects in vascular cells (35). In addition 
to its effects on oxidative stress, oestrogens favourably affect circulating levels of 
lipoprotein. Thus, oestrogens increase HDL-C and apoA1 and decrease LDL-C and 
apoB levels, probably by enhancing the LDL-R activity (38), hence causing a 
beneficial lipid profile. As levels of oestrogens are up to sevenfold higher in pre-
menopausal women compared to men and post-menopausal women, these sex 
hormones are hypothesised to play an important role in the pre-menopausal 
protection (35). 
The risk factors age and gender are closely related in the development of CAD (39). 
This association is established already in puberty, where HDL-C in boys decreases 
markedly, while LDL-C firstly decreases and then rises in late puberty (40). In girls 
minor fluctuations in HDL-C and a markedly decrease in LDL-C is seen during 
puberty (40). These gender differences in lipid levels are not abolished until after 
menopause as total cholesterol and triglycerides has been reported to increase (36). 
Due to this sex divergence, men are exposed to an atherogenic lipid profile for many 
years longer compared to women (40). In addition, other risk factors for CAD as 
abdominal obesity and metabolic syndrome are more pronounced in men, which all 
together may result in an onset of CAD 10-15 years earlier in men compared to 
women (39). Thus, a major fraction of the CAD in men occurs in the middle-age, 
while most CAD cases in women occur after age 65 years.  
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1.2 Atherosclerosis  
1.2.1 Mechanisms Behind Atherosclerosis 
Atherosclerosis is a multi-step, progressive disease which may eventually result in 
blocking of blood supply to the tissues causing e.g. myocardial infarction (MI) or 
stroke (41). Inflammation plays a key role in this process and is present from the 
initiation, during the development of atherosclerotic plaques, and to the endpoint of 
the disease. Dysfunction of the endothelial cells in arteries is supposed to be the 
initial step, which can occur from several factors such as elevated and modified LDL-
C (e.g. oxLDL); free radicals caused by cigarette smoking, hypertension and diabetes 
mellitus, and genetic mutations (31). Due to dysfunctional endothelium, enhanced 
levels of cell adhesion molecules are expressed on the surface and thereby adhere 
increasingly number of monocytes and T lymphocytes (31;41) (Figure 2). In addition, 
an attenuated permeability of the endothelium is established. Fatty streaks, the initial 
lesion of atherosclerosis, are developed by monocytes which migrate through the 
dysfunctional endothelium into the intima and mature to macrophages (41) (Figure 
2). Within the intima, expression of scavenger receptors on the macrophage’s surface 
enables the cells to engulf oxLDL and thus form foam cells by accumulating 
cholesterol esters, seen as fatty streaks in the artery. Sustaining and progression of the 
process is enabled by monocytes, T lymphocytes, SMC, endothelial cells, oxLDL and 
numerous chemokines and cytokines released from the involving cells, all together 
working in concert (31). Formation of an advanced lesion or an atherosclerotic plaque 
occurs as a necrotic core of leukocytes and lipids and a fibrous cap produced of SMC 
and collagen, evolve in the fatty streaks (31;41) (Figure 3). Finally, an inflammatory 
process involving T lymphocytes and several cytokines promote a physical disruption 
of the atherosclerotic plaque, and the thrombus formed is responsible for most of the 
acute cardiovascular events following atherosclerosis (41). 
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Figure 2. Initiating events in the development of a fatty streak lesion. 15-LO= 15 lipoxigenase, ABC-
A1= adenosine triphosphate-binding cassette A1, ACAT= acyl coenzyme A cholesterol 
acyltransferase-1, ApoE= apolipoprotein E, CCR-1= chemokine receptor-1, CD36= cluster designation 
36, CS-1= connecting segment 1, HDL= high density lipoprotein, ICAM= intercellular adhesion 
molecule, INOS= inducible nitric oxide synthase, LDL= low density lipoprotein, MCP-1= monocyte 
chemotactic protein 1, M-CSF= macrophage colony-stimulating factor, SR-A= scavenger receptor A, 
VCAM= vascular cell adhesion molecule. (42) 
 
 
 
Figure 3. Lesion progression. IFNγ= interferon γ, IL= interleukin, Th= T helper cell. (42) 
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1.2.2 Adhesion Molecules 
Adhesion molecules are key mediators responsible for the atherosclerotic initiation; 
the recruitment of the leukocytes from the circulation and their transendothelial 
migration, which is also one of the first signs of inflammation in the atherosclerotic 
process (43;44) (Figure 4). Selectins, immunoglobulin-like molecules and integrins 
are categorised into this group of molecules which are expressed on endothelial cells 
and on circulating leukocytes in response to inflammatory stimuli. As a protective 
mechanism to limit or stop inflammation, adhesion molecules is either cleaved by 
proteases or shed by the cells, resulting in soluble forms (43). Associations between 
certain adhesion molecules and CAD risk are emphasized in several studies (43-45). 
 
Figure 4. Schematic representation of the leukocyte-endothelial cell interaction during the initial steps 
of atherosclerosis, and the role of the different adhesion molecules in this process. ICAM= intercellular 
adhesion molecule, PECAM-1= platelet endothelial cellular adhesion molecule-1, P-sel ligand-1= P-
selectin ligand-1, VCAM-1= vascular cell adhesion molecule-1. (43) 
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Selectins 
This family of adhesion molecules include L-selectin, P-selectin and E-selectin, 
which are all involved in the early leukocyte recruitment by mediating rolling and 
tethering of the leukocytes to the endothelium (43). The selectins interact with their 
ligands and create weak bonds between activated endothelial cells and leukocytes. 
Amplification of the recruitment process is dependent of selectins by their interaction 
between platelets and leukocytes or platelets; or between leukocytes, and hence they 
are contributors to progress the atherosclerosis. L-selectin is constitutively expressed 
on leukocytes (T cells, B cells and natural killer cells), but the degree of expression is 
regulated upon activation of the cells. On the contrary, P-selectin is stored in resting 
cells and is mainly expressed on platelets upon activation. After activation P-selectin 
is expressed within minutes. E-selectin is in detail described beneath.  
E-selectin 
E-selectin is primarily expressed on the surface of activated endothelial cells in 
response to inflammatory cytokines (43). In vitro the cytokines tumor necrosis factor 
α (TNFα) and interleukin (IL)-1β have been shown to induce endothelial expression 
of E-selectin (46;47). However, E-selectin is not stored in the endothelial cells and its 
expression is dependent of cytokine-mediated nuclear factor-κB (NF- κB) induced 
gene transcription, a mechanism involving a cascade of molecules (47;48). This 
induction takes a few hours before E-selectin is expressed on the surface of 
endothelial cells. The disappearance rate of the adhesion molecule from the 
membrane, occurring as internalization or proteolytic cleavage/shedding to the 
extracellular space, is an additional factor important in the regulation of E-selectin 
(47). Soluble E-selectin (sE-selectin) is formed by this proteolytic cleavage/shedding. 
Knock-out mice deficient in E-selectin have been shown to develop fewer arterial 
lesions than normal mice (49;50). Moreover, expression of E-selectin have been 
observed in atherosclerotic plaques (51;52). An observation indicate that sE-selectin 
may serve as a molecular marker for atherosclerosis and the development of CAD, 
since the CAD risk were observed to be two times greater in cases with elevated 
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plasma levels of sE-selectin (53). However, a meta-analysis revealed no significant, 
increased risk for CAD in cases with elevated sE-selectin (44). Thus, this finding 
confirms the need for further investigation of associations between sE-selectin and 
CAD risk. 
Immunoglobulin-like Molecules 
Intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 
(VCAM-1) are members of the immunoglobulin superfamily (54).  
The basal expression level of ICAM-1 in endothelial cells and leukocytes, has been 
shown to increase in vitro at atherosclerotic-prone areas in the aorta in response to 
pro-inflammatory stimuli such as TNFα, oxLDL and LDL (43;45;55). By creating 
strong bonds to integrins on the surface of leukocytes, ICAM-1 has been shown to 
mediate several leukocyte processes; adhesion to activated endothelial cells, arresting 
on the vascular surface and endothelial transmigration (43;54) (Figure 4). A soluble 
type of ICAM-1 (sICAM-1) is formed by shedding (43). 
Deficiency of ICAM-1 in knock-out mice have been suggested to protect against 
atherosclerosis (50;56). Reinforced evidence of associations between ICAM-1 and 
CAD risk have been emphasized as elevated expression of this molecule has been 
observed in atherosclerotic plaques (51;57), and has been suggested to be a predictor 
of cardiovascular disease among healthy individuals (54). 
VCAM-1 is mainly expressed on endothelial cells, but also on macrophages and other 
inflammatory cells (43). Induction of VCAM-1 in vitro is similar to the induction of 
both E-selectin and ICAM-1; TNFα-, IL-1β- and oxLDL-induced up-regulation 
through NF-κB activation (45;47). The expression of VCAM-1 has been observed to 
be increased at atherosclerotic-prone areas of the endothelium. In interaction with 
integrin α4β1, VCAM-1 has been shown to induce signals in endothelial cells that 
trigger changes in shape and allow leukocyte transmigration, and adhere leukocytes 
to activated endothelium (43) (Figure 4). Soluble VCAM- 1 (sVCAM-1) is created by 
proteolytic cleavage (43). 
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Both sICAM-1 and sVCAM-1 are correlated to lipid levels (43), obesity and other 
CAD risks, which suggest that these factors influence the development of CAD (54). 
sVCAM-1 has been observed to be up-regulated at an advanced stage in 
atherosclerosis, suggesting the molecule to be a predictor of mortality among patients 
with existing CAD (54).  
1.2.3 Cytokines 
Another sign of atherosclerosis as an inflammatory disease, is the involvement of 
cytokines from the initiation to the endpoint of the process (55). Cytokines are pro- 
and anti-inflammatory mediators released from cells involved in inflammation, e.g. 
monocytes/macrophages, T cells and endothelial cells. Stimulation of cytokine 
release from these cells is carried out by oxLDL, free radicals, hemodynamic stress, 
hypertension or infectious organisms. They mediate cross-talk between the cells 
resulting in cell activation, differentiation, chemotaxis and proliferation.  
TNFα 
TNFα is a classical pro-inflammatory cytokine, mediating pro-atherogenic processes 
(55). In vitro, TNFα together with other pro-atherogenic cytokines, enhance the 
surface expression of adhesion molecules on endothelial cells, SMC or macrophages. 
T1 lymphocytes mediate increased secretion of TNFα and IL-1β from activated 
macrophages, which is associated with progression of atherosclerosis. Together with 
other pro-inflammatory cytokines, e.g. IL-1α, β and interferon γ (IFNγ), TNFα is 
involved in several inflammatory and atherogenic processes, for instance; foam cell 
formation through e.g. enchanced expression of scavenger receptor on macrophages; 
chemokine release from endothelial cells, SMC and macrophages; activation and 
proliferation of monocytes; apoptosis (programmed cell death) and thrombus 
formation. In these processes TNFα acts by increasing the expression of other 
cytokines, chemokines and growth factors which in turn carry out the performance, 
therefore TNFα seems to be a central mediator in the atherosclerotic process. 
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Gene expression levels of TNFα have been shown to be significantly higher in adult 
FH patients compared to healthy controls, and were also positively correlated to 
plasma total and LDL cholesterol (58).  
1.2.4 Other Inflammatory Markers 
Adiponectin 
Recently, the endocrine function of the adipose tissue has revealed the organ to be 
more than an energy depot (59;60). Adiponectin is a adipokine abundantly and 
exclusively expressed in adipose tissue, in addition the protein is abundant in the 
circulation (61;62). The gene expression of adiponectin is modulated by other 
cytokines secreted from the adipose tissue, such as TNFα (59). Adiponectin levels 
have been observed to be inversely associated with TNFα and C-reactive protein 
(CRP), a strong inflammation marker, in numerous human and mice studies (63). In 
obese children and adolescents decreased levels of adiponectin were also found to be 
associated with higher levels of hs-CRP, low levels of HDL-C and a high 
triglyceride-HDL-C ratio, the two latter are features of metabolic syndrome. These 
findings support a role of adiponectin in obesity, but also in the development of CVD 
(63) probably through their common denominator, inflammation (64). 
Observations that adiponectin suppresses the attachment of monocytes to activated 
endothelial cells and stimulates NO production in vascular cells, which improves 
endothelial function, have suggested that adiponectin have anti-atherogenic properties 
(62). Serum adiponectin has been shown to be closely related to several factors 
important in the progression of CAD in dyslipidemic patients; positively associated 
with HDL-C and negatively associated with high-sensitive CRP (hs-CRP) (65). In 
adolescents and young adults with FH, serum levels of adiponectin have been shown 
to be significantly lower than in healthy controls (61), which may exacerbate the risk 
of premature CAD in adult FH patients (66). However, the association between 
adiponectin and the risk of CAD is still controversial (67). 
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Leptin and Leptin Receptor 
The most abundant expression of leptin, a cytokine-like hormone, is in adipocytes 
(64). Both gene expression and circulating levels of leptin are stimulated by 
inflammatory cytokines such as IL-1β and TNFα (68). Six different leptin receptors 
are known, of which one is soluble and one is widely expressed.  
Although leptin is primarily a regulator of the body’s energy balance (64), its 
function also comprises immunomodulatory effects (68). Mechanisms connected to 
inflammation, involving leptin include e.g. T lymphocyte proliferation, pro-
inflammatory cytokine secretion from T lymphocytes and promoting phagocytic 
function of macrophages. Recently, the hormone has been observed to have free 
radical generating ability, a feature important in the development of atheroslcerosis 
(69). Some types of leptin receptors are involved in the activation of NADPH 
oxidase, and leptin itself have been reported to induce superoxid anion more intensely 
in patients with hypercholesterolemia compared to healthy controls. This free radical 
generating ability is widely accepted to be involved in the foam cell formation 
through the modification of LDL-C forming oxLDL. Moreover, leptin has been 
shown to be able to increase endogenous cholesterol synthesis in human monocytes, 
an effect more pronounced in monocytes from hypercholesterolemic patients, which 
might participate in the progression of an advanced atherosclerotic lesion (69).  
The effect of leptin and leptin receptor deficiency in atherosclerosis is still not clear. 
According to Wu et al. mice lacking both leptin receptor and apoE are more prone to 
develop larger lesions of atherosclerosis compared to apoE deficient mice with 
functional leptin receptor (70). Furthermore, Taleb et al have reported up to 6-fold 
reduction in atherosclerotic lesion development in both leptin and LDL-R deficient 
mice compared to LDL-R deficient mice with similar cholesterol level (64).  
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1.3 Atherosclerosis in Children and Young Adults 
Initiation of atherosclerosis in young adults was described over 50 years ago (71). In 
this study coronary atherosclerosis was found in approximately 77% of the hearts 
dissected from 300 soldiers (average age 22 years) who were killed in war.  
More recently, the Pathobiological Determinants of Atherosclerosis in Youth 
(PDAY) study, a multi-institutional study of atherosclerosis in 15 to 34-year-old 
black and white males and females who died of causes not related to CVD, has 
amplified the findings 50 years ago (72). This study revealed intimal lesions of 
atherosclerosis in all the aortas and in more than half of the right coronary arteries in 
the youngest age group (15-19 years). In the group aged 30-34 years, advanced 
lesions were more prevalent and in larger extent compared to the other age groups in 
both the aorta and the right coronary artery. Risk factors observed to be associated 
with the fatty streaks and the advanced lesions, included VLDL- and LDL-C. HDL-C 
however was inversely associated with the two stages of atherosclerosis. Of the 
trauma victims in the PDAY study, men and women with a favourable lipid profile 
participated in observations of non-lipid risk factors in atherosclerosis (73). Known 
atherosclerotic risk factors such as smoking, hypertension, obesity and impaired 
glucose intolerance were observed to be associated with more extensive lesions in 
persons exposed to these factors. 
The relationship between hypercholesterolemia and premature CAD is well 
established (1-3;31). Children with FH have hence participated in studies to 
understand pathological mechanisms involved in the onset of atherosclerosis (10;74). 
Measurements of the intima-media thickness (IMT) in carotid arteries have been used 
to assess the development of atherosclerosis in children and young adults with FH 
(74;75), since IMT in these arteries has been shown to be associated with MI (74). 
The mean IMT was observed to be significantly greater in children with FH 
compared to age- and sex-matched control subjects (74;75). In 10% of the FH 
children carotid artery plaque was found (74). This was however not seen in the 
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control subjects. Factors related to mean IMT were; gender, LDL-C (74;75), age (75), 
apoB and fibrinogen (74).  
Endothelial dysfunction is crucial in the initiation of atherosclerosis (31), as 
mentioned earlier, and has been reported as a predictor in the future risk of CVD (76). 
OxLDL have been suggested to mediate endothelial dysfunction (31), and indeed 
markers for oxLDL have been shown to be increased in children with FH compared 
to unaffected siblings (77). Furthermore, measurements in FH children have shown 
that endothelial function is impaired in comparison with matched healthy controls, 
and this dysfunction was even more pronounced in FH children with a positive 
family history of premature CVD (76). Strikingly, antioxidant therapy with vitamins 
C (500mg/d) and E (400 IU/d) for 6 weeks in addition to a fat- and cholesterol-
restricted diet for 6 months have been shown to restore endothelial function in 
hyperlipidemic (included FH) children (78).  Similar results have been reported after 
supplementation with DHA (79). 
Lipid levels in FH children are in majority determined by the type of mutation 
causing FH, but other genetic and modifiable environmental factors have also been 
shown to contribute determining the levels, such as serum cholesterol levels in both 
the parents, percent body fat, pubertal stage, sugar intake and apoE genotype (80). In 
fact, a particular genotype, apoE4, has been associated with lower HDL-C levels in 
children with FH, and may thus exacerbate their risk for future CAD (81).   
Recently, regulated on activation normally T-cell expressed and secreted (RANTES) 
and neopterin levels derived from monocytes were shown to be significantly higher 
among children with FH compared to control subjects (10). Adult FH patients did not 
show this elevated level of RANTES. These findings have been amplified by other 
results showing significantly enhanced serum levels of neopterin and hs-CRP in 
children with FH compared to healthy siblings (82). Together, the latter results 
indicate a role of inflammation also in the early stages of atherosclerosis (10;82), and 
suggest that a different inflammatory pattern in children compared to adults might 
exist (10).  
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In conclusion, FH children seem to have a different inflammation pattern. However, 
little is known about early atherosclerotic markers in these children.  
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2. Aims of the Study 
Children with FH are of high interest to study in order to detect pathological 
mechanisms in the early stages of atherosclerosis.  
Few studies have however been conducted to investigate inflammation and markers 
involved in the early atherosclerotic process. We hypothesise that FH children have 
increased levels of early atherosclerotic markers. Therefore, to increase the 
knowledge in this field, more specifically the aims of the following study were: 
1. To compare age- and sex-matched children with and without FH with respect 
to: 
a. circulating levels of early atherosclerotic markers: sE-selectin, 
sVCAM-1 and sICAM-1 
b. gene expression levels of early atherosclerotic markers in circulating 
peripheral blood mononuclear cells (PBMCs): TNFα and ICAM-1 
c. circulating levels of adipokines (leptin and adiponectin) and gene 
expression of leptin receptor in circulating PBMCs 
2. To investigate if there are differences in the same markers in subgroups of the 
FH population according to gender and age.
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3. List of Materials 
Chemicals Distributors 
2 N H2SO4 (stop solution) Merck 
BSA PAA the cell culture company 
DEPC-water Sigma-Aldrich 
Ethanol Arcus Kjemi 
PBS, sterile Sigma-Aldrich 
PBS tablets Gibco 
RNase away Fluka 
Substrate solution Zymed Laboratories 
TaqMan gene expression assay GUSB Applied Biosystems 
TaqMan gene expression assay ICAM-1 Applied Biosystems 
TaqMan gene expression assay Leptin receptor Applied Biosystems 
TaqMan gene expression master mix Applied Biosystems 
TaqMan gene expression assay TBP Applied Biosystems 
TaqMan gene expression assay TNFα Applied Biosystems 
Testoterone Sigma-Aldrich 
TNFα R&D Systems 
Triton X-100 Sigma-Aldrich 
TRIzol reagent  Invitrogen 
Tumor necrosis factor alpha (TNFα) R&D Systems 
Tween Sigma-Aldrich 
  
Kits  
Human Adiponectin Duoset R&D Systems 
Human E-selectin Duoset R&D Systems 
Human ICAM-1 Duoset R&D Systems 
Human Leptin Duoset R&D Systems 
Human VCAM-1 Duoset R&D Systems 
RNA 6000 Nano Kit Agilent 
RNase-free DNase set Qiagen 
RNeasy mini kit  Qiagen 
Superscript™ First-Strand Synthesis System for RT-PCR  Invitrogen 
  
Software  
Genesis Version 3.05 Life Sciences Ltd. 
GraphPad Prism 4 GraphPad Software Inc. 
Microsoft Office Microsoft Inc. 
Reference Manager 11 ISI Research Soft 
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SDS 2.3 Applied Biosystems 
SPSS for Windows SPSS Inc. 
  
Equipment  
24-wells cell culture plates Corning Inc. 
96-wells microplate Costar 
Cell preparation tubes (CPT) BD 
Cell scraper Costar 
MicroAmpTH Optical 96-well Reaction Plate with barcode Applied Biosystems 
Pipette boy IBS Integra Biosciences 
Pipettes Thermo Scientific 
Pipette tips Thermo Scientific 
  
Instruments  
ABI 7900 HT Applied Biosystems 
Agilent 2100 Bioanalyzer  Agilent 
Biofuge, Primo R Heraeus 
Multiskan Ex Thermo Electro Corporation 
Nanodrop ND-1000  Thermo Scientific 
Wellwash 4 MK2 Thermo Electro Corporation 
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4. Subjects and Methods 
4.1 Subjects 
Sixty-two children 7-20 years of age with heterozygous FH were recruited 
consecutive from the nationwide competence centre for children with FH at the Lipid 
Clinic, Rikshospitalet University Hospital, Oslo, Norway. All the children were 
diagnosed with definite FH by DNA test, but were clinically healthy without any 
diagnosis of CAD, and none were on current statin treatment. Twenty-two healthy, 
age- and sex-matched children without hypercholesterolemia, recruited among 
friends of the FH children or children of the staff at the hospital were asked to take 
part in the study as a control group. Written informed consent was obtained from all 
of the participants ≥18 years or from 1 parent when the child was <18 years. The 
study was approved by the Regional Committee of Medical Ethics. 
4.2 Blood Samples 
Venous blood samples were collected from all the participants of the study from year 
2003-2007 by Holven et al (10). Serum samples were immersed in melting ice and 
allowed to clot for 1 hour before centrifugation (1000 g, 10 minute [min], room 
temperature [rt]) (83). The samples were divided into multiple aliquots and stored at -
80ºC. Limited blood samples from each individual made it impossible to perform all 
the analyses from all of the children. PBMCs were available in 34 of the FH subjects 
and 12 of the control subjects. Baseline parameters such as total cholesterol, LDL-C, 
HDL-C, apoB and apoA1 were measured by the Department of Medical 
Biochemistry, Rikshospitalet University Hospital, Oslo, Norway. 
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4.3 Isolation of PBMCs 
Background 
PBMCs include monocytes and lymphocytes, cells which are central in inflammation 
and hence in the atherosclerosis process. At the latter point of view, initial activation 
of these cells is carried out by endothelial dysfunction, enable them to increase the 
expression of and release of cytokines, chemokines and receptors for adhesion 
molecules (31). Thus, alterations in gene expression levels in these cells are 
demonstrable early in the process before signs of inflammation can be seen in vivo. 
Further activation retains the PBMCs participating during the whole atherogenesis 
and in concert with cytokines, adhesion molecules, chemokines and endothelial cells 
they finally form an atherosclerotic lesion (31). However, their high availability and 
the fact that they are exposed to many of the same environmental factors as the 
intima, where the atherogenesis takes place, make them suitable for studying gene 
expression levels of mediators involved in the development of CAD (84). Contrary to 
red blood cells, PBMCs have a nucleus which is crucial to synthesize ribonucleic acid 
(RNA). 
Procedure 
Cell preparation tubes (CPT) (Catalogue # 362761, BD) were used for the isolation of 
PBMCs to be used for the quantitative reverse transcription polymerase chain 
reaction (Q-RT-PCR), and the method used is based on the same principles as the 
method described by Schlenke et al (85).  
CPT were centrifuged at 1600 g, rt for 20 min after approximately 45 min on the 
bench. Red blood cells and granulocytes penetrated through the gel-layer, while 
PBMCs formed a whitish layer just beneath the plasma layer on top, see Figure 5. 
The PBMCs were then transferred into a new tube and washed twice with phosphate 
buffered saline (PBS) (Catalogue # P3813, Sigma). After centrifugation with PBS 
(300 g, rt, 10 min), the pellet from the PBMCs was stored at -80 ºC before TRIzol 
treatment and isolation of RNA. 
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Figure 5. Cell preparation tube. 
4.4 Isolation of RNA 
Background 
Isolation of RNA was performed through a combination of TRIzol Reagent 
(Catalogue # 15596-018, Invitrogen) and RNeasy mini kit (Cataloge # 74104, 
Qiagen). Use of the TRIzol Reagent is an improvement of the single-step RNA 
isolation method developed by Chomeczynski et al (86) which allows RNA to 
separate from DNA after extraction under acidic conditions using guanidinium 
thiocyanate, phenol and chloroform (87). The TRIzol Reagent (containing phenol and 
guanidine isothiocyanate) is a denaturant which lyses the cell, dissolves the cell 
components and maintains intact RNA by denaturing endogenous RNase (88). 
Addition of chloroform and following centrifugation performs two phases, an organic 
and an aqueous one. Extraction of RNA by phenol/chloroform leaves RNA 
exclusively in the aqueous phase. Ethanol will then precipitate RNA from the 
aqueous phase and leave proteins and disposal behind in the supernatant. The RNeasy 
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spin columns collect RNA and purification can be combined with RNase-free DNase 
set (Catalogue # 79254, Qiagen) (89) which digests genomic DNA (gDNA) in the 
sample and hence avoids spurious results in Q-RT-PCR. 
Procedure 
The method used is described by de Vries et al (90). In order to avoid degradation of 
RNA by RNAse, isolation hood and all equipment were cleaned with RNase away 
and subsequently diethylpyrocarbonate (DEPC) water (Catalogue # W4502, Sigma). 
The pellet from the PBMCs was resuspended in TRIzol reagent immediately after 
transferring from the freezer and incubated for 5 min. Chloroform was added and the 
sample was subsequently centrifuged (12000 g, 4ºC, 15 min). The aqueous phase was 
transferred into a new tube and added 70% ethanol (diluted in DEPC water and made 
fresh every time) (Catalogue # 60068, Arcus Kjemi). Further, the solution was 
transferred to an RNeasy column, washed with several buffers and purified with a 
DNase mix (10:80 DNase stock 1 solution and RDD buffer). Several washing steps 
with two different buffers were carried out, before RNA was eluted in RNase free 
water (30μl). Distribution of the sample into several tubes avoids several cycles of 
freezing and thawing which decreases degradation of RNA later in the process and 
was done as a final step. Finally, the samples were stored at -80ºC. 
4.5 Quantification and Qualification of RNA 
4.5.1 Quantification 
Background 
The Nanodrop ND-1000 spectrophotometer (Thermo Scientific) enables RNA 
quantification by sending a light through the sample and analyzing the intensity (91).  
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Procedure 
Prior to quantification, the samples were thawed on ice and centrifuged briefly. The 
instrument requires 1 μl, but to ensure enough volume, 1.2 μl were added onto the 
end of the fibre optic cable (91). 
4.5.2 Qualification 
Background 
RNA integrity is of high importance for application in Q-RT-PCR, as short fragments 
in a degraded RNA can cause unreliable results in the relative quantification (92;93). 
The Agilent 2100 Bioanalyzer (Agilent Technologies) in combination with the RNA 
6000 Nano Kit (Part # 5067-1511, Agilent Technologies) enables a qualification of 
RNA by utilizing the capillary forces in an electrophoresis provided by the Lab on a 
Chip technique (Agilent Technologies) (94). Voltage-induced size separation of RNA 
subunits in gel-filled channels, is described in a curve of an electropherogram (Figure 
6) (93). The curve shows peaks of RNA subunits, and two peaks are essential for 
achieving a high integrity: the 18S and 28S ribosomal RNA (rRNA) subunits (95). A 
well established algorithm of RNA integrity, the RNA integrity number (RIN) 
counting from 1 to 10 (best), is based on several features of RNA integrity. One is the 
total RNA ratio of areas under the 18S and the 28S peaks compared to the area under 
the whole curve (93). 
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Figure 6. Electropherogram of intact total RNA from a sample with a RIN 9.2 (A) and of partially 
degraded total RNA from a sample with a RIN 5.8 (B). 18S= subunit of ribosomal ribonucleic acid, 
28S= subunit of ribosomal ribonucleic acid, RNA = ribonucleic acid, RIN= ribonucleic acid integrity 
number. (95) 
Procedure 
The method used is described in the user’s manual on Agilent’s homepage (96). 
Agilent RNA 6000 Nano Kit (Part # 5067-1511, Agilent) was equilibrated to rt 30 
min before use.  
Gel matrix was centrifuged (1500 g, 10 min, rt) and subsequently 65μl were 
portioned into a new tube. Preparing the gel-dye mix involved mixing dye 
concentrate in the gel mix and centrifuge (13000 g, 10 min, rt). A RNA 6000 Nano 
chip were put in the chip priming station and loaded with the gel-dye mix in the well 
marked G in a circle. By means of air pressure the plunger distributed the gel-dye mix 
all over the chip. Another two amounts of gel-dye mix were loaded into the wells 
marked G. RNA 6000 Nano marker were added in all the 12 sample wells and the 
ladder well. Both samples and ladder were added into the chip, in one well each and 
the well marked with symbol ladder, respectively. Ladder and samples were 
denatured (2 min, 70 ºC), before loading on the chip.  
The chip was vortexed horizontally in the adapter for 1 min and ran in the Agilent 
2100 Bio Analyzer immediately. To avoid any RNase contamination of analysis, the 
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electrodes were decontaminated with both “RNase away” (Catalogue # 83931, Fluka) 
and DEPC-water before inserting the chip. 
Samples reaching a RIN above 6 (n=34 FH and n=12 control subjects) were further 
synthesised to cDNA and determined by Q-RT-PCR.   
4.6 First-strand cDNA Synthesis 
Background 
The first-strand cDNA synthesis provides a transcript (cDNA) of gene expression 
(messenger RNA [mRNA]) which is further used for gene quantification in Q-RT-
PCR (97).  This reaction requires a short single stranded oligonucleotide (primer) for 
the enzyme which catalyzes the cDNA synthesis reaction. Primers are 
complementary to a known sequence initially of the transcription area. The Oligo dT 
primer is used for its specification to hybridize to poly-A-tails, which are particularly 
found on the vast majority of eukaryotic mRNA (97). Catalyzation of the cDNA 
synthesis reaction is performed by the reverse transcriptase (RT), the Superscript™ 
II, because of its reducing effect on RNase H activity. This both improves the 
synthesis of full-length cDNA and gives higher yields of first-strand cDNA compared 
to other RTs. Deoxyribonucleotide triphosphate (dNTP) mix contains the nucleotides 
of which the cDNA is synthesised of and thus is consumed by the Superscript™ II 
RT in the reaction. Removal of RNA template in the cDNA sample can increase the 
sensitivity of PCR from cDNA and is done by RNase H in the final step of first-
strand synthesis of cDNA.  
Procedure 
Both the procedure (97) and the kit, Superscript™ First-Strand Synthesis System for 
RT-PCR (Catalogue # 11904-018, Invitrogen), were from Invitrogen. Amounts 
equivalent 500 ng total RNA were transferred to a new tube to perform cDNA, and 
added oligo dT, dNTP mix and DEPC-water. The components annealed at 65 ºC, 5 
min, before cooling on ice ≥ 1 min. Reaction mix (10x RT buffer, 25mM MgCl2, 0,1 
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M DTT and RNase Out) were added before incubation (42 ºC, 2 min). Immediately 
after incubation, the samples were added RT while still staying on the heat block. The 
samples were further incubated at same temperature in 50 min. To terminate the 
reactions, the samples were transferred to 70 ºC for 15 minutes before cooling on ice. 
As a final step, RNase H was added to the samples, and incubated (37 ºC, 20 min). 
The samples were placed on ice and then stored at -80ºC.  
4.7 Q-RT-PCR 
Background 
In basic research, the Q-RT-PCR is a widely used tool to determine, characterise and 
quantify gene expression (98). Quantification by this method is based on the 
equation: N = N0 (1+E)n, where N is the number of amplified sequences after n cycles 
of amplification, N0 is the initial number of target sequences and E is the efficiency of 
amplification per cycle (99).  
Single-stranded cDNA performed in the first strand cDNA synthesis is applied as a 
template for amplification in the Q-RT-PCR (100). Table 2 shows the course in the 
PCR using TaqMan gene expression assay. The AmpErase Uracil-N-Glycosylase 
(UNG) activation avoids PCR contamination as it destroys both single- and double-
stranded dU-containing DNA (101). Two steps in PCR are temperature sensitive 
(100). Initially, denaturation of template DNA is ensured by a temperature at 95ºC, 
this enables the primers to anneal to their target sequence in the second step, which is 
set to a temperature at 60 ºC. This step is critical in the PCR as too high temperature 
results in a reduced number of amplification products because of poorly annealed 
primers (102). If the temperature is too low, primers may anneal to non-specific 
sequences and cause spurious amplification products. After primer annealing, 
extension of the target sequence is carried out by the polymerase. Forty cycles of 
denaturation, annealing and DNA synthesis is then repeated. 
Compared to the traditional PCR, using agarose gel to detect PCR amplification in 
the plateau phase of the reaction, Q-RT-PCR method measures the cycles of 
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amplification in the exponential phase of the reaction (103). The TaqMan chemistry 
assay for Q-RT-PCR (Applied Biosystems) consists of two primers and a fluorogenic 
probe which is sequence-specific to the target sequence (100). An intact probe has a 
reporter dye, 6-carboxyfluorescein (FAMTM) bound to the 5’-end and a quencher on 
the 3’-end, which highly reduces the fluorescence emitted by the reporter by 
receiving the energy by the fluorescence resonance energy transfer. However, if the 
target sequence is present the probe anneals between the forward primer and the 
reverse primer. Q-RT-PCR starts and the probe is cleaved by the polymerase during 
extension, causing fluorescence (100). Reliable results are achieved by normalization 
of the fluorescent emission using a passive reference, 6-Carboxyl-X-Rhodamine 
(ROXTM), calculating a ratio between the FAMTM dye emission and the ROXTM 
emission, the Rn value (100). Further, the Rn value is used to determine ∆ Rn which is 
defined as: Rn – baseline, where baseline is the initial cycles of Q-RT-PCR where 
there is little change in the fluorescent signal. The point in time when the ∆ Rn 
crosses a fixed level (threshold) is defined as the threshold cycle (CT). An 
amplification plot graphically displays the CT and the fluorescence detected over the 
number of cycles that were performed (Figure 7) (100). 
Manually calculation of the final results also requires quantification of an endogenous 
control from every experimental sample, which means a gene with a stable 
expression in all the samples.  
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Table 2. Conditions in the PCR. 
 
Adapted from Applied Biosystems (100). DNA= deoxyribonucleic acid, PCR= polymerase chain 
reaction, UNG= uracil-N-glycosylase. 
 
 
Figure 7. Amplification plot of the endogenous control TBP consisting of 27 individual samples 
showing ∆ Rn vs cycle. ∆ Rn = (fluorescence emission of reporter dye/fluorescence emission of 
reference dye)-baseline. Cycle shows how many amplification cycles the PCR has performed. The 
green line represents threshold. PCR= polymerase chain reaction, TBP= TATA box binding protein. 
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Procedure 
The standard curve method was chosen in this procedure and it was made of an equal 
amount cDNA from all the samples (n= 49) and diluted 1:2 in DEPC-water to a four 
point curve with the highest concentration of 50 ng. Every cDNA sample was diluted 
in DEPC-water to a working concentration of 5 ng/μl. Q-RT-PCR was performed by 
using TaqMan Gene Expression assay (Applied Biosystems). The TaqMan gene 
expression master mix (Part # 4369514, Applied Biosystems), containing AmpliTaq 
Gold® DNA polymerase, Uracil-DNA Glycosylase (similar to AmpErase UNG), 
dNTP, ROXTM and buffers (104), was blended with the primer solution (consisting of 
primers [900 nM] and the TaqMan probe [200 nM], both specific to the target 
sequence) and DEPC-water, and added to every single well on a 96-well standard 
plate. Both standards and samples were added in triplicates on the plate in accordance 
with a specific layout. DEPC-water was used as a blank control. The plate 
(MicroAmpTH Optical 96-well Reaction Plate with barcode, part # 4314320, Applied 
Biosystems) was centrifuged (1200 rpm, 1 min, rt) and ran in the ABI 7900 HT 
(Applied Biosystems) immediately for one and a half hour on the 96-well standard 
block. Testing genes are shown in Table 3. The principles of the PCR amplification 
method is shown in Figure 8. 
 
Table 3. Genes tested in Q-RT-PCR. 
      
   
Target Gene type Assay number from Applied Biosystem 
   
ICAM-1 testing Hs00164932_m1 
   
Leptin receptor testing Hs00174497_m1 
   
TNFα testing Hs00174128_m1 
   
TBP housekeeping Hs00427620_m1 
   
GUSB housekeeping Hs99999908_m1 
   
GUSB = β-glucuronidase, ICAM-1= intercellular adhesion molecule 1, TBP = TATA box binding 
protein, TNFα= tumor necrosis factor α. 
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Figure 8. Amplification of DNA by PCR the region of DNA to be amplified is flanked by two sequences 
used to prime DNA synthesis. The starting double-stranded DNA is heated to separate the strands and 
then cooled to allow primers (usually oligonucleotides of 15 to 20 bases) to bind to each strand of 
DNA. DNA polymerase from Thermus aquaticus (Taq polymerase) is used to synthesize new DNA 
strands starting from the primers, resulting in the formation of two new DNA molecules. The process 
can be repeated for multiple cycles, each resulting in a twofold amplification of DNA. DNA= 
deoxyribonucleic acid, PCR= polymerase chain reaction. (105) 
4.8 Sandwich Enzyme Linked ImmunoSorbant Assay 
(ELISA) 
Background 
The sandwich ELISA technique is based on the analyte-binding capacity of 
antibodies (106). Initially, all wells in a microtiter plate are coated with an analyte-
specific capture antibody which will capture the molecules to measure e.g leptin. 
Before the samples/standards are incubated with the capture antibodies, a blocking 
 49
reagent is added to avoid unspecific binding of the samples/standards. This reagent is 
ousted by the samples/standards in the incubation. A detection antibody is added and 
binds to a different epitope of the molecule which is measured. This aggregate is 
detected by a reagent, streptavidin-horseradish-peroxidase (HRP), an enzyme which 
emits colour (blue) when it converts a substrate. Finally, a stop solution (2 N H2SO4) 
is terminating the enzyme reaction and changing the colour from blue to yellow. High 
colour intensity reflects high concentration of the molecule which is measured. The 
optical density (OD) of the colour can be measured by a microtiter plate reader. 
Between every step in the procedure, except the last one, washing steps are carried 
out to remove unbound antibodies/analytes.  
Procedure  
The method used is based on the user’s manual on R&D’s homepage (107). All wells 
in a microtiter plate was incubated with capture antibody (diluted in PBS [working 
concentration differs from the molecule to be measured]) in rt over night before 
washing with wash buffer (0.05% Tween 20 [Catalogue # 90005-64-5, Sigma-
Aldrich] in PBS). Blocking the whole plate with Reagent Diluent (1% Bovine Serum 
Albumine [BSA] [Catalogue # K41-001, PAA the cell culture company] in PBS) was 
carried out and incubated for 1 hour. Washing step was repeated. Both samples 
(diluted in Reagent Diluent in an appropriate concentration) and standards, a seven 
point standard curve using a 2-fold serial dilutions in Reagent Diluent (highest 
concentration differs from the molecule to be measured), were added to their 
respective wells and incubated for 2 hours. Washing step was repeated. Detection 
antibody (diluted in Reagent Diluent [working concentration differs from the 
molecule to be measured]) were subsequently added in all wells and incubated for 2 
hours. A new washing step was carried out. Streptavidin-HRP (working dilution: 
1:200 in Reagent Diluent) were then added in all wells and incubated in room 
temperature for 20 minutes in a dark place. Washing step was repeated. A substrate 
solution (Catalogue # 00-2023, Zymed Laboratories) was added to all the wells and 
the plate was incubated in room temperature for 20 minutes in a dark place. 
Terminating the procedure was done by adding stop solution (2 N H2SO4) (Catalogue 
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# 3.0731.1, Merck) to all the wells and immediately measuring the OD at a 
wavelength of 450 nm. The procedure was carried out in accordance with 
manufacturer’s instructions. Testing molecules are listed in Table 4. 
 
Table 4. Molecules tested in sandwich ELISA. 
    
  
Molecules Catalogue # from R&D systems 
  
Leptin DY398 
 
 
 
 
  
sICAM-1 DY720
  
sVCAM DY809
  
sE-selectin DY724
  
Adiponectin DY1065
  
ELISA= enzyme linked immunosorbant assay, sICAM= soluble intercellular adhesion molecule-1, 
sVCAM= soluble vascular cell adhesion molecule, sE-selectin= soluble E-selectin. 
4.9 Hormone Levels 
The serum levels of the sex hormones, testosterone and sex hormone binding 
globuline (SHBG) were determined at the Hormone laboratory, Aker University 
Hospital, Oslo. Free androgen index (FAI) was calculated as the ratio between 
testosterone and SHBG, and accounts for the fraction of testosterone which is bound 
to SHBG (108). 
4.10 Statistical Analysis 
Data are given in median values (range) unless otherwise stated. The non-parametric 
Mann-Whitney test was used to determine significant differences between FH 
children and control subject, and between subgroups in the FH population. 
Correlations in the FH population, the control subjects and within FH subgroups were 
calculated by the non-parametric Spearman coefficient. Data in the pilot small study 
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of statin treatment were tested with Wilcoxon signed rank test. Pearson’s Chi Square 
test was used when data were given as < or > than certain values, such as in the 
variables testosterone, SHBG and FAI. Statistical significance was determined by a 
p-value <0.05.
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5. Results 
5.1 Characterisation of the Subjects 
Characterisation of the subjects is shown in Table 5. Serum concentrations of total 
cholesterol, LDL-C and apoB were significantly higher in the FH population 
compared to healthy control subjects. However, HDL-C and apoA1 were not 
significantly different between the two groups.  
 
Table 5. Baseline characteristics of the participants. 
      
 FH Controls 
   (n=62)  (n= 22) 
   
Age, years 14.5 (7-20) 16 (11-19) 
   
Male gender, % 54 41 
   
Total cholesterol, mmol/L 7.1 (4.4-10.6) * 4.1 (2.4-4.9) 
   
LDL cholesterol, mmol/L 5.3 (2.8-8.7) * 2.6 (1.2-3.4) 
   
HDL cholesterol, mmol/L 1.3 (0.8-2.1) 1.5 (1.0-2.1) 
   
ApoA1, g/L 1.2 (0.9-2.1) 1.3 (0.7-1.7) 
   
ApoB, g/L 1.2 (0.6-1.8) * 0.6 (0.2-0.7) 
   
Data are presented in median values (range). ApoA1/B were available in n=44 FH children and n=20 
control subjects. *p<0.01 vs control subjects. ApoA1= apolipoprotein A1, apoB= apolipoprotein B, FH= 
familial hypercholesterolemia, HDL= high density lipoprotein, LDL= low density lipoprotein. 
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5.2 FH Children versus Control Subjects 
5.2.1 Early Atherosclerotic Markers 
First we analysed whether there was a difference in the circulating levels of the early 
atherosclerotic markers sE-selectin, sVCAM-1 and sICAM-1 in children with and 
without FH. We found that there was a trend towards increased levels of sE-selectin 
(Figure 9A) in the FH population compared to the control subjects, p=0.082. There 
were no significant differences in the circulating levels of sVCAM-1 (Figure 9B) and 
sICAM-1 (Figure 9C). Levels of the measured atherosclerotic markers in the FH 
group compared to the control subjects are listed in Table 6.  
 
Figure 9. Circulating levels of sE-selectin (A), sVCAM (B) and sICAM-1 (C) in FH children (n=62) and 
in age- and sex-matched control subjects (n=22). Horizontal bars represent median values. FH= 
familial hypercholesterolemia, sE-selectin= soluble E-selectin, sICAM-1= soluble intercellular adhesion 
molecule-1, sVCAM-1= soluble vascular cell adhesion molecule-1.  
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Table 6. Levels of the circulating inflammation markers in the FH population and 
the control subjects. 
      
 FH population Control subjects  
  (n=62) (n=22) 
   
sE-selectin, ng/ml 38 (11-98) 28 (7-58) 
   
sICAM-1, ng/ml 46 (36-54) 46 (38-54) 
   
sVCAM-1, ng/ml 38 (23-44) 35 (23-41) 
   
Leptin, ng/ml 6 (1-81) 7 (1-71) 
   
Adiponectin, ng/ml 677 (110-1360) 522 (209-1430) 
   
Data are presented in median values (range). FH= familial hypercholesterolemia, sE-selectin= soluble 
E-selectin, sICAM-1= soluble intercellular adhesion molecule-1, sVCAM-1= soluble vascular cell 
adhesion molecule-1.  
 
In order to investigate if there were differences in the gene expression of early 
atherosclerotic markers between the FH children and the control children gene 
expression of TNFα and ICAM-1 from isolated PBMCs were analysed. Significant 
increased levels of TNFα gene expression (Figure 10A) was observed in the FH 
population compared to the control subjects, p=0.019. There was however no 
significant difference in ICAM-1 levels (Figure 10B). 
 
Figure 10. Gene expression levels of TNFα (A) and ICAM-1 (B) in FH children (n=34) and control 
subjects (n=12). Endogenous controls are defined by the mean gene expression of TBP and GUSB. 
Horizontal bars represent median values. FH= familial hypercholesterolemia, GUSB= β-glucuronidase, 
ICAM-1= intercellular adhesion molecule, TBP= TATA box binding protein, TNFα= tumor necrosis 
factor α.  
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5.2.2 Adipokines and Leptin Receptor 
Numerous studies suggest an association between leptin and serum cholesterol levels 
(69;109-112), and in addition adiponectin has been shown to be related to 
hyperlipidemia (61;62;67). FH children are characterised by increased levels of total 
cholesterol and LDL-C compared to healthy controls. We therefore investigated 
whether there were differences in the levels of leptin, adiponectin and the gene 
expression of the leptin receptor in PBMCs from children with and without FH. No 
significant differences however, were found in the levels of leptin (Figure 11A), 
adiponectin (Figure 11B) or in the gene expression of the leptin receptor (Figure 
11C) between the two groups. Levels of the measured adipokines in the FH group 
compared to the control subjects are listed in Table 6. 
 
Figure 11. Serum levels of leptin (A) and adiponectin (B) in FH children (n=62) and control subjects 
(n=22), and gene expression levels of leptin receptor (C) in FH children (n=34) and control subjects 
(n=12). Endogenous controls are defined by the mean gene expression of TBP and GUSB. Horizontal 
bars represent median values. FH= familial hypercholesterolemia, GUSB= β-glucuronidase, TBP= 
TATA box binding protein.  
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5.2.3 Correlations 
We next analysed whether there was correlations between the baseline characteristics 
and the tested parameters in all the participants. Several correlations were found 
between baseline characteristics and testing parameters in the study population (Table 
7). The main findings include positive correlations between some of the early 
circulating atherosclerotic markers, sE-selectin, sICAM-1, sVCAM-1 and the gene 
expression of TNFα (Table 7). Adiponectin was inversely correlated to age, whereas 
leptin was positively correlated to age. A similar pattern was found when the 
correlations were performed in the FH group and the control group, separately (see 
Appendix, Table I and II, respectively). In addition inverse correlations were 
observed between the early atherosclerotic markers sICAM-1, sVCAM-1 and TNFα 
gene expression, and LDL-C, total cholesterol and apoB in the FH population (see 
Appendix, Table I). This was however not seen in the whole study population, neither 
in the control group separately. The inverse correlation between age and adiponectin, 
and a positive correlation between age and leptin were only observed in the FH 
population and not in the control group separately.  
When puberty starts, the circulating levels of cholesterol (both for FH children and 
control children) are reduced (113), probably due to an increased synthesis of the 
steroid sex hormones, a mechanism which is probably more pronounced among 
children with FH compared to healthy control children. This cholesterol decrement in 
adolescence should be regarded by clinicians, particularly in diagnosis of children 
with FH. Since we found an inverse correlation between total cholesterol and LDL-C, 
and sICAM-1 and VCAM-1 in the FH population, we correlated the circulating 
markers and the lipid parameters in the oldest age group of the whole study 
population. When looking at the correlations only in children above 15 years (n=43) 
we found significant, positive correlations between sE-selectin, sICAM-1 and 
sVCAM-1, and apoB, r=0.383, p=0.031; r=0.525, p=0.02 and r=0.395, p=0.025 
respectively. 
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Table 7. Correlations in the study population (n=84). 
                  
       mRNA mRNA 
    Adiponectin sE-selectin sICAM-1 Leptin sVCAM-1 TNFα 
Leptin 
receptor
         
Total cholesterol Correlation coefficient 0.226    
 p-value 0.039    
     
LDL-C Correlation coefficient 0.257    
 p-value 0.021    
     
ApoB Correlation coefficient 0.257    
 p-value 0.038    
     
sE-selectin Correlation coefficient 0.329 -0.248   
 p-value 0.002 0.023   
     
sICAM-1 Correlation coefficient 0.329  0.698 0.551  
 p-value 0.002  0.000 0.000  
     
Leptin Correlation coefficient -0.248    
 p-value 0.023    
     
sVCAM-1 Correlation coefficient 0.698   0.553  
 p-value 0.000   0.000  
     
mRNA ICAM-1 Correlation coefficient   -0.330
 p-value   0.025
    
Age Correlation coefficient -0.381 0.246  
  p-value 0.000   0.024      
         
Not all parameters were available in all participants. ApoA1= apolipoprotein A1, apoB= apolipoprotein 
B, ICAM-1= intercellular adhesion molecule-1, LDL-C= low density lipoprotein cholesterol, mRNA= 
messenger ribonucleic acid, sE-selectin= soluble E-selectin, sICAM-1= soluble intercellular adhesion 
molecule-1, sVCAM-1= soluble vascular cell adhesion molecule, TNFα= tumor necrosis factor α. 
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5.3 Gender and Age 
Gender has been shown to be a risk factor in CAD in the adult population 
(34;38;114). In addition, some studies have shown a gender difference of higher sE-
selectin levels in men compared to women (114;115) and a significant positive 
correlation between sVCAM-1 and age was found by Blann et al (115). 
5.3.1 Characterisation of the FH Population Subdivided According 
to Gender 
Characterisation of the FH children separated in boys and girls is shown in Table 8. 
No significant differences in the baseline parameters were found between the two 
groups. 
 
Table 8. Baseline characteristics of the FH children separated in boys and girls. 
      
 FH boys FH girls 
  (n=33) (n=29) 
   
Age, years 14 (7-20) 15 (9-18) 
   
Total cholesterol, mmol/L 7.0 (4.4-10.3) 7.3 (4.4-10.6) 
   
LDL cholesterol, mmol/L 5.3 (3.3-8.0) 5.5 (2.8-8.7) 
   
HDL cholesterol, mmol/L 1.3 (0.9-2.0) 1.3 (0.8-2.1) 
   
ApoA1, g/L 1.2 (0.9-1.7) 1.1(0.9-2.1) 
   
ApoB, g/L 1.2 (0.6-1.8) 1.3 (0.6-1.7) 
   
Data are presented in median values (range). ApoA1/B were not available in all the participants. 
ApoA1= apolipoprotein A1, apoB= apolipoprotein B, FH= familial hypercholesterolemia, HDL= high 
density lipoprotein, LDL= low density lipoprotein. 
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5.3.2 Gender and Early Atherosclerotic Markers 
We next analysed whether there was a gender difference in the levels of sE-selectin, 
sVCAM-1 and sICAM-1 in the FH population. Increased levels of sE-selectin (Figure 
12A) and sVCAM-1 (Figure 12B) were observed in FH boys compared to FH girls, 
p=0.006 and p=0.051 respectively. However, no significant difference was found in 
sICAM-1 (Figure 12C). Levels of the early circulating atherosclerotic markers among 
boys and girls in the FH population are listed in Table 9. There were no significant 
differences in the levels of sE-selectin, sVCAM-1 and sICAM-1 between FH boys 
and control boys or between FH girls and matched controls (data not shown).  
 
Figure 12. Circulating levels of sE-selectin (A), sVCAM (B) and sICAM-1 (C) among boys (n=33) and 
girls (n=29) in the FH children. Horizontal bars represent median values. FH= familial 
hypercholesterolemia, sE-selectin= soluble E-selectin, sICAM-1= soluble intercellular adhesion 
molecule-1, sVCAM-1= soluble vascular cell adhesion molecule-1. 
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Table 9. Levels of the circulating inflammation markers in boys and girls with FH. 
      
 FH boys FH girls 
  (n=33) (n=29) 
   
sE-selectin, ng/ml 42 (13-98)** 30 (11-80) 
   
sICAM-1, ng/ml 46 (40-54) 45 (36-53) 
   
sVCAM-1, ng/ml 38 (23-44)* 36 (23-43) 
   
Leptin, ng/ml 3 (1-32)** 18 (2-81) 
   
Adiponectin, ng/ml 577 (110-1360) 687 (107-1130) 
   
Data are presented in median values (range). *p=0.051, **p<0.01 vs FH girls. FH= familial 
hypercholesterolemia, sE-selectin= soluble E-selectin, sICAM-1= soluble intercellular adhesion 
molecule-1, sVCAM-1= soluble vascular cell adhesion molecule. 
At gene expression level, we analysed whether there was a difference in the 
inflammation markers TNFα and ICAM-1 in FH boys and girls. There were however 
no significant differences between the genders in either TNFα or ICAM-1 (Figure 
13A and B respectively). We also wanted to investigate if there were differences 
between FH girls and boys and their control counterparts. There was a trend towards 
higher gene expression levels of TNFα in FH girls compared to control girls, p=0.08 
(data not shown). This was however not observed between FH boys and control boys 
(data not shown). There were no significant differences between either FH boys and 
control boys or FH girls and matched controls in the gene expression of ICAM-1 
(data not shown). 
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Figure 13. Gene expression levels of TNFα (A) and ICAM-1 (B) among boys (n=22) and girls (n=12) in 
the FH population. Endogenous controls are defined by the mean gene expression of TBP and GUSB. 
Horizontal bars represent median values. FH= familial hypercholesterolemia, GUSB= β-glucuronidase, 
ICAM-1= intercellular adhesion molecule-1, TBP= TATA box binding protein, TNFα= tumor necrosis 
factor α. 
5.3.3 Gender, Adipokines and Leptin Receptor 
Leptin, adiponectin, and the gene expression of leptin receptor were analysed among 
boys and girls with FH. As expected, we found significant increased level of leptin in 
FH girls compared to FH boys (Figure 14A), p=0.000. There were however no 
significant differences either in adiponectin (Figure 14B) or in the gene expression of 
the leptin receptor (Figure 14C). Levels of the adipokines are listed in Table 9. We 
also investigated if FH girls and boys had differences in the levels of adipokines and 
leptin receptor than their control counterparts. FH girls tended to have enhanced 
leptin levels (18 [2-81] ng/ml) than control girls (10 [3-71] ng/ml), p=0.09. This was 
not observed between FH boys and control boys. There were no significant 
differences in the levels of adiponectin or the gene expression levels of leptin 
receptor between either FH girls and control girls, or FH boys and matched controls 
(data not shown).  
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Figure 14. Levels of adiponectin (A) and leptin (B) among boys (n=33) and girls (n=29) in the FH 
population, and the gene expression of leptin receptor (C) among boys (n=22) and girls (n=12) in the 
FH population. Endogenous controls are defined by the mean gene expression of TBP and GUSB. 
Horizontal bars represent median values. FH= familial hypercholesterolemia, GUSB= β-glucuronidase, 
TBP= TATA box binding protein. 
5.3.4 Age  
The gender differences in the levels of sE-selectin (Figure 12A), sVCAM-1 (Figure 
12B) and leptin (Figure 14A) led us to hypothesise differences in age groups as well. 
Therefore, we also wanted to see if there were differences in the measured markers 
when subdividing the FH children in age groups, above and below 15 years (median 
age). There were no significant differences either in the levels of sE-selectin (Figure 
15A), sVCAM-1 (Figure 15B) or sICAM-1 (data not shown) in FH children above 
and below the age of 15. However, there was a trend towards increased levels of 
leptin in FH children above 15 years compared to FH children below 15 years, 
p=0.075 (Figure 15C). Moreover, the levels of adiponectin were significantly 
decreased in FH children above 15 years compared to FH children below 15 years, 
p=0.000 (Figure 15D). Levels of the circulating inflammation markers are listed in 
Table 10. 
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Figure 15. Levels of sE-selectin (A), sVCAM-1 (B), leptin (C) and adiponectin (D) in the FH subgroups 
below (n=31) and above 15 years (n=31). Horizontal bars represent median values. FH= familial 
hypercholesterolemia, sE-selectin= soluble E-selectin, sVCAM-1= soluble vascular cell adhesion 
molecule-1, y= years. 
 
Table 10. Levels of the circulating inflammation markers in the FH population 
subdivided in age groups above and below 15 years. 
      
   
  FH children <15 y FH children >15 y 
   
sE-selectin, ng/ml 36 (11-98) 39 (11-92) 
   
sVCAM-1, ng/ml 36 (23-43) 39 (23-44) 
   
Leptin, ng/ml 5 (2-29) 9 (1-81) 
   
Adipoenctin, ng/ml 717 (167-1360)* 494 (107-958) 
   
Data are presented in median values (range). *p<0.01 vs FH children >15 y. FH= familial 
hypercholesterolemia, sE-selectin= soluble E-selectin, sVCAM-1= soluble vascular cell adhesion 
molecule-1, y= years. 
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5.3.5 Gender and Age 
When we subdivided the FH children according to both gender and age, we found 
that there were significantly enhanced levels of sE-selectin in boys above 15 years 
(Figure 16A) compared to FH girls in the same age group, p=0.019. For sVCAM-1 a 
trend towards increased levels in boys below 15 years (Figure 16D) was observed 
compared to FH girls in the same age group, p=0.068. As expected, there were 
significantly enhanced levels of leptin in girls above 15 years (Figure 16 E) compared 
to FH boys in the same age group, p=0.000. Furthermore, a trend towards enhanced 
levels of leptin in FH girls below 15 years (Figure 16F) compared to FH boys in the 
same age group was also observed, p=0.068. Levels of the circulating inflammation 
makers are listed in Table 11.  
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Figure 16. The FH population subdivided in boys above 15 years (n=15) and girls above 15 years 
(n=16) and boys below 15 years (n=18) and girls below 15 years (n=13) showing levels of sE-selectin 
(A and B), sVCAM-1 (C and D) and Leptin (E and F), respectively. Horizontal bars represent median 
values. FH= familial hypercholesterolemia, sE-selectin= soluble E-selectin, sVCAM-1= soluble 
vascular cell adhesion molecule-1, y= years. 
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Table 11. Levels of the circulating inflammation markers in the FH population 
subdivided according to gender and age. 
          
 FH boys >15 y FH girls >15 y FH boys < 15 y FH girls <15 y 
  (n=15) (n=16) (n=18) (n=13) 
     
sE-selectin, ng/ml 47.3 (13.0-92.0)* 27.0 (11.2-80-0) 40.0 (22.9-98.3) 32.9 (11.1-56.9) 
     
sVCAM-1, ng/ml 39.4 (23.3-43.5) 37.5 (22.9-43.4) 37.9 (26.7-42.9)# 31.2 (22.9-40.1) 
     
Leptin, ng/ml 2.4 (1.3-31.6)** 37.2 (8.1-81.3)§ 3.7 (1.6-20.5)# 8.3 (2.0-28.8) 
     
Adiponectin, ng/ml 473 (110-928)¤ 541 (107-958)װ 707 (167-1360) 871 (203-130) 
     
Data are presented in median values (range). *p<0.05, **p<0.01 vs FH girls >15 y. ¤p<0.01 vs FH 
boys <15 y. §p<0.01 vs FH girls <15 y. װp<0.05 vs FH girls <15 y. #p=0.068 vs FH girls <15 y. FH= 
familial hypercholesterolemia, sE-selectin= soluble E-selectin, sVCAM-1= soluble vascular cell 
adhesion molecule-1, y= years. 
 
We also investigated whether FH girls below 15 years differed from FH girls above 
15 years, and likewise in FH boys. FH girls above 15 years have increased leptin 
levels compared to FH girls below 15 years (Figure 17A). This was not seen in FH 
boys above and below 15 years. Furthermore, FH girls above 15 years (Figure 17B) 
have significantly decreased adiponectin levels compared to FH girls below 15 years, 
the same result was seen in FH boys (Figure 17C), p=0.008 and p=0.012 respectively. 
When subdividing the control subjects likewise, no differences were observed (data 
not shown). Levels of the circulating inflammation markers are listed in Table 11.  
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Figur 17. Levels of leptin (A) and adiponectin (B) in FH girls below (n=13) and above (n=16) 15 years, 
and levels of adiponectin (C) in FH boys below (n=18) and above (n=15) years. FH= familial 
hypercholesterolemia, y= years. 
5.4 Sex Hormones 
Some studies emphasise that sex hormones is involved in the induction of adhesion 
molecule expression on endothelial cells (46;116). The observation that elevated sE-
selectin levels only were present in FH boys above 15 years compared to age-
matched FH girls and not in the gender groups below 15 years, led us to hypothesise 
that sex hormones were involved in this mechanism. We subsequently analysed the 
levels of testosterone and SHBG and calculated the FAI. Serum samples available 
were n=58 from FH children and n=19 from control subjects. The levels of 
testosterone, SHBG and FAI in the FH children and the control subjects subdivided 
in boys and girls are shown in Table 12. We found as expected increased testosterone 
levels (p<0.01) and FAI (p<0.01) among FH boys compared to FH girls, however 
there were no differences observed between FH boys and control boys. In Table 13 
the levels of these parameters in the FH children subdivided in both age and gender 
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are listed. We then analysed whether the SHBG, testosterone and FAI were correlated 
to the circulating early atherosclerotic markers and serum cholesterol. We found an 
inverse correlation between total cholesterol, testosterone and FAI (Table 14). In 
addition testosterone was positively correlated to all the circulating early 
atherosclerotic markers, sE-selectin, sICAM-1 and sVCAM-1 (Table 14) whereas 
FAI was positively correlated to sE-selectin and sICAM-1.  
 
Table 12. Levels of testosterone, SHBG and FAI in the FH children (n=58) and the 
control subjects (n=19) subdivided in boys and girls. 
          
 FH boys FH girls Control boys Control girls 
  (n=31) (n=27) (n=9) (n=10) 
     
Testosterone, nmol/l 10.0 (<0.5-28.7) 1.0 (<0.5-4.3) 13.3 (<0.5-23.8) 1.0 (<0.5-1.9) 
     
SHBG, nmol/l 51 (15-175) 67 (8->180) 39 (14-103) 58 (37->180) 
     
FAI 0.26 (0-1.41) 0.02 (0-0.13) 0.61 (0-1.05) 0.02 (0-0.03) 
     
Data are presented in median values (range). FAI= free androgen index, FH= familial 
hypercholesterolemia, SHBG= sex hormone binding globuline. 
 
Table 13. Levels of testosterone, SHBG and FAI in the FH children (n=58) 
subdivided in age and gender. 
          
 FH boys >15 y FH girls >15 y FH boys <15 y FH girls <15 y 
  (n=13) (n=16) (n=18) (n=11) 
     
Testosterone, nmol/l 17.8 (7.6-28.7) 1.4 (0.7-4.3)** 6.7 (<0.5-17.9) <0.5 (<0.5-1.2) 
     
SHBG, nmol/l 34 (15-75) 57 (8->180) 66 (19-175) 79 (30-120) 
     
FAI 0.57 (0.24-1.41)# 0.03 (0-0.13)* 0.68 (0-0.84) 0.01 (0-0.03) 
     
Data are presented in median values (range). #p=0.069 vs FH boys <15 y. **p<0.01 vs FH girls <15 y. 
*p<0.01 vs FH girls <15 y. FAI= free androgen index, FH= familial hypercholesterolemia, SHBG= sex 
hormone binding globuline. 
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Table 14. Correlations between hormones, serum cholesterol and early 
atherosclerotic markers in the FH population (n=58). 
          
     
    SHBG Testosterone FAI 
   
Total cholesterol Correlation coefficient -0.416 -0.345 
 p-value 0.001 0.008 
   
LDL-C Correlation coefficient -0.405 -0.321 
 p-value 0.002 0.014 
   
HDL-C Correlation coefficient 0.404 -0.286 
 p-value 0.002 0.014 
   
ApoB Correlation coefficient -0.334 -0.315 
 p-value 0.029 0.040 
   
sE-selectin Correlation coefficient 0.301 0.285 
 p-value 0.022 0.030 
   
sVCAM-1 Correlation coefficient 0.404 0.330 
 p-value 0.002 0.012 
   
sICAM-1 Correlation coefficient 0.363 0.310 
  p-value  0.005 0.018 
     
FAI= free androgen index, FH= familial hypercholesterolemia, HDL-C= high density lipoprotein 
cholesterol, LDL-C= low density lipoprotein cholesterol, SHBG= sex hormone binding globulin, sE-
selectin= soluble E-selectin, sICAM-1= soluble intercellular adhesion molecule-1, sVCAM-1= soluble 
vascular cell adhesion molecule. 
5.5 Effects of Statin Treatment – A Pilot Study 
In five of the FH children, samples before and after statin treatment (with treatment 
duration of 4-80 weeks) were available. These samples were used as a small 
preliminary pilot study to see whether statin treatment could have an effect on any of 
the markers measured. We found a trend towards a reduction of sE-selectin levels 
after treatment with statins compared to baseline measurements, p=0.08 (Table 15). 
This finding indicates a need to further explore the effect of statin on early 
atherosclerotic markers. 
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Table 15. Levels of circulating inflammation markers before and after statin 
treatment in the FH children (n=5). 
      
   
  Before  After 
   
sE-selectin, ng/ml 35.6 (16.3-65.3) 26.8 (8.6-55.0) 
   
sICAM-1, ng/ml 41.7 (39.7-44.0) 43 (40.0-45.4) 
   
sVCAM-1, ng/ml 26.4 (23.3-28.8) 27.1 (20.1-31.9) 
   
Adiponectin, ng/ml 472 (258-695) 623 (336-764) 
   
Leptin, ng/ml 4.6 (3.3-27.8) 7.2 (1.8-19.5) 
   
Data are presented in median values (range). FH= familial hypercholesterolemia, sE-selectin= soluble 
E-selectin, sICAM-1= soluble intercellular adhesion molecule-1, sVCAM-1= soluble vascular cell 
adhesion molecule-1.
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6. Discussion 
6.1 Discussion of Methods 
6.1.1 Methods for Isolating PBMCs and RNA 
Use of gene expression in PBMCs has several advantages in determining possible 
risk markers in CVD (117). Since plasma/serum levels of molecules may not reflect 
their production by specific tissues, measurements of gene expression in the specific 
tissue involved in the process is a better approach. Thus, gene expression in PBMCs 
may be used in the understanding of cardiovascular conditions (117), as PBMCs are 
exposed to many of the same environmental factors as the intima, where the 
atherogenesis takes place (84). One crucial factor when consider them as a model is 
their ability to synthesise RNA, in addition their high availability is very 
advantageous. When investigating genes in the lipid metabolism, PBMCs may not be 
the most suitable model, however they are very suitable when studying other 
atherosclerotic markers. However, immediately after leaving their environment, the 
gene expression in the PBMCs may be altered due to stress (99). Therefore it is 
important to use a rapid method when isolating PBMCs. 
CPT is an easy and to our knowledge the most rapid method for isolation of PBMCs 
(118). The method should hence be performed continuously and performance-time 
should be shortened where this is possible, as this performance is a critical step for 
further analysis of PBMCs. Although use of the TRIzol reagent inhibits RNase 
degradation of the samples and delivers high yields of RNA (87), caution must be 
taken as the reagent constitute health risk (119). In combination with the RNeasy 
columns, RNAse-free DNase treatment of the samples avoids gDNA contamination 
and thus increases the fidelity in further analysis (98).  
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6.1.2 Q-RT- PCR 
Q-RT-PCR was used to quantify mRNA levels in PBMCs due to its simplicity, 
specificity and demand for small amounts of mRNA (120). In the Q-RT-PCR target 
genes are detected in the exponential phase of the reaction (103). This contributes to a 
very precise measurement since none of the reaction components are consumed or 
none of the Q-RT-PCR products are degraded in the exponential phase. This enables 
maximal reaction efficiency and an exact doubling of products in this phase.  
However, there are several pitfalls in the steps prior to and during the Q-RT-PCR 
method (92). Since quantitative detection of a target is dependent of the template 
abundance (120), both quality and quantity of RNA should be assessed prior to 
cDNA synthesis (92;121). We determined the quality of all the samples in the Agilent 
2100 Bioanalyzer, which has been shown to be one of the most accurate qualifying 
methods (121). To ensure complete cDNA synthesis, only RNA samples with a RIN 
above 6 and a gel free of smear were chosen in further analysis. Measurements of 
RNA quantity were performed by the Nanodrop ND-1000. For normalisation of 
sample size, all samples synthesised to cDNA had amounts of 500 ng total RNA, 
which is within the range of use in Q-RT-PCR (100 pg -1 μg) (99). Template 
abundance may also be poor if cDNA synthesis is inadequate. Oligo dT was used as 
primer in the cDNA synthesis due to its specificity targeting poly-A-tails present in 
the vast majority of mRNA (97). However, drawbacks of using oligo dT is 
incomplete cDNA when targeting RNA with low integrity (99). Normalisation to 
endogenous controls which are constantly expressed in all cells independent of 
experimental conditions controls for internally errors in Q-RT-PCR (121;122). 
However, choice of endogenous controls remains as a major problem in Q-RT-PCR 
(98;121;122). Two of the classically used endogenous controls, glyceraldehyd-3-
phosphate dehydrogenase and β-actin, have been reported to be inappropriate for 
normalisation in the Q-RT-PCR (121). Therefore, we used GUSB and TBP which 
have to our previous experience shown to be constantly expressed in PBMCs. 
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6.1.3 Sandwich ELISA 
Sandwich ELISA is a rapid, simple, specific and sensitive method for measuring 
protein quantity (123). In addition, the protein binding capacity of the plates is high 
and thus the method requires low sample volume. Awareness should be taken as 
plates made of different material bind protein different e.g. some material types have 
high binding to protein, but increase “noise” (124). In the Sandwich ELISA method 
all samples are related to a standard curve, and hence a poor standard curve may give 
spurious results (125). Inaccurate results may also occur if: incubation times are not 
kept; incubation temperatures vary; the content of the wells evaporate. 
6.1.4 Subjects and Statistics 
Although the number of participants is acceptable compared to other published 
studies similar to the present one (10;82), limitations are still connected to the number 
of participants in several of our statistical analysis. In analysis where the FH 
population and the control subjects have been subdivided according to gender and/or 
age, the number of participants is too small to be representative. Particularly this is 
pronounced among the control subjects whose number is below the half of the 
number of participants in the FH population. Thus, we assume that in some statistical 
analysis significant results will not appear due to the small number of participants. On 
the other hand, even in some of the small test groups significant results appear, which 
may suggest strong associations between the tested markers and the subjects. Since 
normal distribution was mainly not obtained, statistically non-parametric methods 
were used throughout.  
6.2 Discussion of Results 
The main findings of the present study are: i) FH children have increased TNFα gene 
expression levels and a tendency to increased sE-selectin levels compared to control 
children; ii) FH boys have enhanced sE-selectin and sVCAM-1 levels compared to 
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FH girls; iii) FH boys above 15 years have increased levels of sE-selectin compared 
to age-matched FH girls; iv) FH boys below 15 years have enhanced levels of 
sVCAM-1 compared to FH girls in the same age group; v) FH girls have enhanced 
leptin levels compared to FH boys; vi) there was a tendency to enhanced leptin levels, 
whereas adiponectin levels were decreased in FH children above 15 years compared 
to FH children below 15 years. Taken together these results may support and confirm 
the observation of increased inflammation and further extends the knowledge of early 
inflammation markers in FH children. This in turn may contribute to understand the 
early atherosclerotic processes.  
6.2.1 Inflammatory Markers 
TNFα can be seen as a key mediator in the development of atherosclerosis due to its 
involvement in the recruitment of inflammation cells, the formation of foam cells and 
fatty streaks, the cellular activation and proliferation, and finally in the thrombus 
formation (55). Enhanced secretion of TNFα from T cells, macrophages and foam 
cells due to inflammatory response, leads to further activation of these cells and a 
positive feedback on the secretion of TNFα. The increased gene expression levels of 
TNFα seen in the present study may suggest enhanced inflammation in FH children. 
In fact, these increased levels in PBMCs may also contribute locally to progress the 
inflammation and hence the atherosclerotic process in the intima after the 
transendothelial migration of the PBMCs. 
E-selectin is primarily expressed by endothelial cells in response to inflammatory 
stimuli such as TNFα, but is almost absent under normal conditions (43). In order to 
limit or stop an inflammatory process, E-selectin is either internalised and degraded 
in lysosomes or shed/proteolytically cleaved by the endothelial cells, the latters 
resulting in circulating levels of this molecule. It is thus conceivable that the tendency 
towards increased levels of sE-selectin seen in FH children may be due to increased 
surface expression of E-selectin as a response to inflammatory mediators, a process 
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resulting in dysfunction of endothelial cells which in fact is previously shown to be 
significantly more pronounced in FH children compared to control subjects (22). 
Previously, FH children have been shown to have a significant increased gene 
expression of RANTES and elevated circulating levels of neopterin compared to 
healthy control children, indicating the presence of a proinflammatory monocyte 
(10). Furthermore, others have also reported elevated circulating levels of neopterin, 
and increased circulating levels of hs-CRP in children with FH compared to control 
children (82). Our findings are consistent with these observations, and together they 
suggest an enhanced inflammation already present in children with FH. TNFα have 
been found to up-regulate neopterin levels (10). Thus, the increased gene expression 
levels of TNFα in PBMCs from FH children may potentially increase serum 
neopterin levels and may thus partly explain the previous findings.  
Studies have shown that circulating levels of TNFα may predict cardiovascular 
events in humans (126-128). In these studies circulating levels of TNFα were 
suggested to be an independent predictor of risk for cardiovascular events in patients 
with unstable angina (126), and in healthy individuals (127;128). Moreover, 
circulating levels of TNFα were correlated to several established CVD risk factors 
e.g. LDL-C (127). Observation of increased gene expression levels of TNFα in adult 
FH patients, which have an increased risk of premature CAD, compared to healthy 
adult controls (58), may support the findings above. However to our knowledge, 
increased gene expression of TNFα already in children with FH has not previously 
been reported.  
In vitro, TNFα acts by increasing the surface expression of the early atherosclerotic 
markers, ICAM-1, VCAM-1 and E-selectin on endothelial cells, SMC and 
macrophages (55). Indeed we found a significant correlation between gene expression 
levels of TNFα and sICAM-1 and sVCAM-1. The two circulating adhesion 
molecules, sICAM-1 and sVCAM-1 have previously been reported to predict CVD in 
different manners (53;129-132). sICAM-1 have been suggested to be a predictor of 
CVD in healthy adult individuals (129;130;133), whereas sVCAM-1 levels are 
 78 
enhanced in adult patients with risks of CVD, and may hence predict future 
cardiovascular events or cardiovascular mortality (131;132;134). 
In fact, TNFα may also mediate an indirect effect on the adhesion molecules through 
the up-regulation of CD40 and CD40 ligand (CD40L), cell-associated members of 
the TNF family. Subsequent binding of CD40 and CD40L may in turn enhance the 
surface expression levels of ICAM-1, VCAM-1 and E-selectin on the same cells 
mentioned above. However, serum levels of soluble CD40L (sCD40L) were not 
different between FH children and unaffected siblings (82). Thus, the increasing 
effect of TNFα on sCD40L is probably a pathway activated later in the atherogenesis 
as enhanced levels of sCD40L are regarded as a reliable marker of enhanced platelet 
activation (82).  
An interesting finding in our study is the gender difference in the levels of circulating 
early atherosclerotic markers in the FH population. Here we show that FH boys are 
characterised by elevated levels of sE-selectin and sVCAM-1.  
In the adult population gender difference for developing CAD is well established, 
where pre-menopausal women have a significantly decreased risk of developing 
CAD compared to age-matched men (34). Indeed, boys with FH have significantly 
thicker mean IMT of the carotid artery than FH girls (75), and a correlation between 
male gender and greater IMT has also been observed (74). When it comes to early 
atherosclerotic markers, increased sE-selectin and soluble P-selectin (sP-selectin) 
levels have been observed in men compared to age-matched women (114). Our study 
is to our knowledge, the first report showing that gender differences in the levels of 
sE-selectin and sVCAM-1 are present already in children with FH. 
The gender difference in the levels of sE-selectin was only apparent in the FH 
population among the children above 15 years, whereas levels of sVCAM-1 showed 
a tendency to be higher in FH boys below the age of 15 compared to FH girls in the 
same age group. Together with sICAM-1, sE-selectin and sVCAM-1 were 
significantly correlated to the levels of testosterone in the FH population.  
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Regarding inflammation in atherosclerosis, effects of testosterone in vitro are 
reported to increase both mRNA and protein expression of E-selectin and VCAM-1 
in human umbilical vein endothelial cells (HUVEC) stimulated with TNFα (46). 
Additionally, testosterone has been associated with increased total and LDL 
cholesterol and has been shown to increase atherosclerosis in primates and rabbits 
(135). Thus, the previously mentioned functions of testosterone may explain the 
increased risk of developing CAD in men compared to women, a gender difference in 
the risk of CAD which exists already when the boys enter puberty and lasts until the 
women pass by menopause (34). On the other hand, testosterone administration has 
been shown to decrease atherosclerosis in castrated male rabbits, and androgens seem 
in fact to have an antiatherogenic effect in men (135). Hence, the effect of 
testosterone in atherosclerosis is still unclear. 
Surprisingly, in the FH population, we found an inverse correlation between total 
cholesterol and LDL-C and the early atherosclerotic markers (Appendix, Table I). 
Total and LDL cholesterol have been shown to decrease in the first period of puberty 
(from 9-15 years of age) (113), probably caused by increased production of sex 
hormones. Because of the enhanced cholesterol levels it is likely that this feature is 
more pronounced in an FH population. In our study a positive correlation was found 
between apoB and the early atherosclerotic markers in the oldest age group (above 15 
years). ApoB and/or LDL-C levels have previously been shown to be associated with 
early atherosclerotic changes in the carotid arteries, and in addition apoB has been 
significantly associated with carotid artery IMT in children with and without FH (74). 
In summary, it seems that increased levels of testosterone (maybe in combination 
with the enhanced cholesterol level) may lead to increased levels of sE-selectin which 
again over time will aggravate the FH boys’ risk for developing CAD compared to 
FH girls.  
Since the increased levels of sVCAM-1 and sE-selectin differed in FH boys below 15 
and above 15 years, sVCAM-1 may be differently regulated compared to sE-selectin. 
Below the age of 15 years FH boys have significantly decreased levels of testosterone 
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compared to FH boys above 15 years. Hence the tendency towards a higher level of 
sVCAM-1 may be influenced by other factors. Children with FH have been shown to 
have higher levels of oxLDL antibodies compared to control subjects (77). Since 
elevated LDL-C and/or oxLDL are suggested to cause endothelial dysfunction (31), 
these factors may potentially result in the tendency towards higher sVCAM-1 levels 
in FH boys below 15 years.  
In five of the FH children serum samples before and after a period of statin treatment 
were available. We did a very small pilot study to see whether there were differences 
in the levels of the early atherosclerotic markers. Even in this small group of FH 
children we found a trend towards a reduction in the levels of sE-selectin (p=0.08). 
This is consistent with the finding showing that early statin treatment has a beneficial 
effect on endothelial function (22). In fact, decreased gene expression levels of E-
selectin and VCAM-1 have been reported in HUVEC stimulated with TNFα in the 
presence of statin (47). The protein expression levels of E-selectin were however 
increased, whereas the levels of VCAM-1 were decreased after statin stimulation. 
This may be explained by inhibited disappearance rate of E-selectin from the 
endothelial surface after statin stimulation (47), and different time-regulation 
compared to expression of VCAM-1. Thus, it is not impossible that these effects of 
statins also operate in FH children, and may be responsible for the improvement of 
the endothelium seen in FH children after statin treatment (22). In addition, a recent 
study has shown that early initiation of statin treatment in FH children (8-18 years) 
was associated with a smaller IMT (14). Taken together these findings support early 
initiation of statin treatment in children with FH.  
According to the NCEP guidelines for drug therapy recommendations in children, 
male gender is a risk factor in which drug therapy in children below 10 years with 
high-risk lipid abnormalities is considered (16). Our results support and strengthen 
this recommendation for initiation of statin therapy in boys before puberty as an 
attempt to abolish the adverse effects of testosterone on the early atherosclerotic 
markers later in puberty.  
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6.2.2 Adipokines and Leptin Receptor 
There were no significant differences in the levels of adiponectin, leptin or leptin 
receptor in the FH population compared to the control subjects.  
Adiponectin have recently been inversely correlated to markers of endothelial 
dysfunction and systemic inflammation, and hence suggested to be an important 
mediator in the development of CVD (63). Previously, decreased levels of 
adiponectin have been observed in both adolescent and middle-aged hyperlipidemic 
patients (61;62). Our results are inconsistent with these observations and suggest that 
the levels of adiponectin do not diverge in children with and without FH. Regarding 
the age of the adolescent participants in the previous study all the participants were 
below the age of 30 years and the mean age was approximately 20 years (61). In our 
study median age was 14.5 years in FH children and 16 years in control subjects. This 
difference in age may explain the opposing results between the two studies and may 
suggest that the decrement in serum levels of adiponectin occurs later in the 
atherosclerotic process. In fact, we have shown that serum levels of adiponectin are 
significantly decreased in FH children above 15 years compared to FH children 
below 15 years. This age difference was not seen when subdividing the control 
subjects likewise. In addition, inverse correlations were found between adiponectin 
levels and age only in the FH group. Although the number of control subjects were 
fewer, these results may suggest that adiponectin levels decrease with increasing age 
in FH children while the levels of adiponectin may stay constant in control children. 
However, more studies are needed to determine whether adiponectin levels decrease 
in adolescents with a risk of premature CVD.  
Leptin has been linked to atherosclerosis through its pro-inflammatory effects (68). In 
dyslipidemic patients enhanced leptin levels have been observed compared to control 
subjects (111). The elevated levels of leptin in these patients correlated with higher 
BMI (111), a relation which is well established (136). However, children with FH are 
not charaterised by having higher BMI than control subjects (82), which might 
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explain why leptin levels in children with and without FH do not differ in the present 
study. 
Not surprisingly, levels of leptin were significantly increased in FH girls compared to 
FH boys, and the difference was most pronounced in FH girls above 15 years. Gender 
divergence in serum levels of leptin where women have significantly enhanced levels 
of leptin is well established (136). This is probably caused by different levels of sex 
hormones and different amount of body fat mass in men and women. Our finding is 
consistent with this knowledge. A trend towards increased leptin levels in FH girls 
compared to control girls was additionally observed. However, an important finding 
is that FH girls above 15 years have significantly increased leptin levels compared to 
FH girls below 15 years. This finding was not present in control girls when 
subdividing likewise. Again, the small number of control girls might explain why we 
can not observe any age difference. Regarding the levels of leptin it is still tempting 
to suggest that FH girls may have increased levels of leptin compared to healthy girls. 
A possible explanation may be that LDL-C (which is significantly higher among FH 
girls) in combination with oestrogens may exacerbate this leptin profile in FH girls. 
Further investigation is needed to detect whether leptin levels really differs in girls 
with FH compared to control girls.  
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7. Conclusion and Clinical Implications 
In the present study we have shown that:  
1. FH children have an increased inflammatory profile compared to healthy 
control children, shown by: 
a. tendency towards increased sE-selectin levels 
b. significantly increased levels of TNFα gene expression 
2. There are subgroup differences in atherosclerotic markers within the group of 
FH children: 
a. boys have significantly increased levels of sE-selectin and sVCAM-1 
compared to girls 
b. boys above 15 years have significantly enhanced levels of sE-selectin 
compared to girls in the same age group 
c. boys below the age of 15 years have enhanced sVCAM-1 levels 
compared to girls in the same age group  
d. girls above 15 years have significantly enhanced levels of leptin 
compared to boys with in the same age group 
e. children above 15 years have significantly decreased levels of 
adiponectin compared to children below 15 years 
In conclusion, our results may support the notion of increased inflammation in FH 
children. Furthermore, the results may also indicate that the gender difference in the 
levels of early atherosclerotic markers may be established already in childhood and 
may thus partly explain the gender difference in the risk of CVD. Based on these 
findings it may be suggested that initiation of statin treatment in FH children should 
start early in an attempt to reduce the levels of early atherosclerotic markers. 
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Initiation of statin treatment before puberty in boys may be of particularly importance 
to abolish the assumed adverse effect of testosterone on these markers.  
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8. Future Perspective 
The present study has generated new questions and hypothesis. 
8.1 Early Atherosclerotic Markers 
Since we found significantly increased gene expression levels of TNFα in PBMCs 
from FH children compared to control subjects, we speculate that serum levels of 
TNFα may be enhanced in the same population as well. This will be investigated as 
one of the next steps. According to the in vitro effects of TNFα on the adhesion 
molecules (55), it is conceivable that serum levels of TNFα may be connected to 
these molecules. A link between TNFα and the trend towards an increased level of 
sE-selectin seen in FH children might be found when correlating these markers.  
Furthermore, we want to investigate other early atherosclerotic markers, such as sP-
selectin and fractalkine. P-selectin is another adhesion molecule involved in the 
recruitment and adhesion of leukocytes to the endothelium (43), and thus may be 
increased in the early steps of atherosclerosis. Additionally, gender differences in 
levels of sP-selectin have been observed in adults (114), and we wonder whether this 
gender difference is present already in FH children. Another adhesion molecule, 
fractalkine, which is expressed on endothelial cells upon stimulation of e.g. TNFα  is 
also of interest (137). Together with its chemotactic effect, its adhesive properties 
support a presence of the molecule early in the atherosclerotic process.  
8.2 Adipokines 
The observed trend in increased leptin levels in FH girls compared to control girls 
needs further investigation. Therefore we want to increase the number of subjects and 
perform further analysis regarding leptin levels in girls. Visfatin, another adipokine, 
have been associated with cardiovascular conditions (138), and we want to 
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investigate if FH children have a different level of this marker. CD36, or the 
scavenger receptor expressed on macrophages, is responsible for the engulfing of 
modified LDL by macrophages in the intima (31). Thus, CD36 is involved in the 
early steps of atherosclerosis by contributing to formation of foam cells and fatty 
streaks. Furthermore, Rodenburg et al have shown that FH children have enhanced 
levels of some oxLDL antibodies compared to control subjects (77). Therefore, we 
want to investigate whether gene expression levels of CD36 is upregulated in FH 
children compared to control children. 
8.3 Effects of Statin Treatment 
Since the levels of sE-selectin had a tendency to be decreased by statins in the small 
preliminary pilot study, we want to collect a larger number of FH children before and 
after statin treatment in order to confirm whether statins really reduce sE-selectin and 
other early atherosclerotic markers. This collection of samples has already started and 
will be continued and analysed during the autumn 2008. 
8.4 Screening of New Genes Involved in Early 
Atherosclerosis 
In order to detect more genes which may be modified in FH children compared to 
control children, a microarray will be conducted. FH children with extremely high 
levels of LDL-C and severe, pathological family history of CAD, and age- and sex-
matched control children will participate in this analysis.  
8.5 In Vitro Effects of OxLDL and Testosterone 
Previously, testosterone has been shown to increase expression of E-selectin and 
VCAM-1 in TNFα stimulated HUVEC (46). We speculate that testosterone and/or in 
combination with oxLDL may mediate increased expression of E-selectin and 
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VCAM-1 therefore we want to investigate the expression of these atherosclerotic 
markers on the surface of HUVEC after stimulation in presence or absence of 
testosterone, oxLDL and TNFα. 
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10. Appendix 
Table I. Correlations in the FH population (n=62). 
                
       mRNA 
    Adiponectin sE-selectin sICAM-1 Leptin sVCAM-1 TNFα 
        
Total cholesterol Correlation coefficient 0.252 -0.407  -0.413 -0.551
 p-value 0.048 0.001  0.001 0.001
   
LDL-C Correlation coefficient -0.508  -0.459 -0.632
 p-value 0.000  0.000 0.000
   
ApoB Correlation coefficient -0.360  -0.386 -0.561
 p-value 0.015  0.009 0.004
   
Age Correlation coefficient -0.466 0.294 
 p-value 0.000 0.021 
   
sE-selectin Correlation coefficient 0.331  0.278
 p-value 0.009  0.029
   
sICAM-1 Correlation coefficient 0.331  0.746 0.513
 p-value 0.009  0.000 0.002
   
Leptin Correlation coefficient -0.330  
 p-value 0.009  
   
sVCAM-1 Correlation coefficient 0.278 0.746  0.442
 p-value 0.029 0.000  0.009
   
mRNA ICAM-1 Correlation coefficient  0.375
  p-value       0.029
        
Not all the parameters were available from all the participants. ApoB= apolipoprotein B, FH= familial 
hypercholesterolemia, LDL-C= low density lipoprotein cholesterol, sE-selectin= soluble E-selectin, 
sICAM-1= soluble intercellular adhesion molecule-1, sVCAM-1= soluble vascular cell adhesion 
molecule-1, TNFα= tumor necrosis factor α. 
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Table II. Correlations among the control subjects (n=22). 
              
     mRNA mRNA mRNA 
    sE-selectin sVCAM-1 leptin receptor TNFα ICAM-1 
   
LDL-C Correlation coefficient  -0.746
 p-value  0.013
   
ApoB Correlation coefficient -0.502 0.455  
 p-value 0.024 0.044  
   
sICAM-1 Correlation coefficient 0.582  0.713
 p-value 0.005  0.009
   
sVCAM-1 Correlation coefficient 0.580 0.615 -0.853
 p-value 0.048 0.033 0.000
   
mRNA leptin receptor Correlation coefficient  -0.587
 p-value  0.045
   
mRNA ICAM-1 Correlation coefficient -0.853 -0.587 
  p-value  0.000 0.045   
       
Not all the parameters were available from all the participants. CRP= C-reactive protein, ICAM-1= 
intercellular adhesion molecule-1, LDL-C= low density lipoprotein cholesterol, mRNA= messenger 
ribonucleic acid, sICAM-1= soluble intercellular adhesion molecule-1, sVCAM-1= soluble vascular cell 
adhesion molecule, TNFα= tumor necrosis factor α.

 
